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Background: Multiple sclerosis (MS) is a chronic demyelinating disorder of the 
central nervous system that can lead to severe disability. It is a complex disease likely 
caused by genetic and environmental factors combined. Epstein-Barr virus (EBV) 
infection, low vitamin D, smoking, and being overweight are the environmental 
factors, which have most consistently been associated with an increased MS risk. 
However, detailed aspects of their involvement are not entirely resolved. Timing of 
exposure appears to be important, but whether the effect of vitamin D on 
susceptibility varies by age is unclear. Further, while a link between being overweight 
and MS risk has consistently been reported among women, it is less clear among 
men. Still, as the cause of MS is ultimately unknown, research on new potential 
etiologic factors is also warranted. One attractive candidate is physical exercise, as it 
is modifiable and could prevent disease if proven effective. Etiologic research can be 
facilitated if the natural history of MS is well characterized and understood. However, 
the nature and timing of prodromal MS, i.e. subclinical disease activity before the 
onset of classic neurologic symptoms, is largely unknown, and is thus a challenge to 
studies of risk factors and relevant timing. 
Objectives: The main objectives in this thesis were to gain knowledge on 
susceptibility periods and prodromal MS and advance research on established and 
putative new environmental risk factors. In detail, we intended to 1) investigate the 
association between postnatal timing of cod liver oil use, an important oral vitamin D 
source in Norway, and MS risk, 2) compare cognitive performance of men who later 
in their life developed MS to those who did not, to capture potential differences 
indicative of disease processes prior to first symptom and therefore prodromal MS, 
and 3) examine the association between being overweight and MS risk in men and 
whether fitness, as a proxy of exercise, is independently related to disease risk. 
Methods: For the first objective, we used the Norwegian data of the multi-national 
population-based case-control study Environmental Factors in Multiple Sclerosis 
(EnvIMS). We included, in total, 953 MS cases with neurologist-verified diagnosis 
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recruited from the Norwegian MS registry and with disease duration of maximally 10 
years, and 1,717 controls randomly selected from a population registry, frequency-
matched on sex and age. Participants reported their cod liver oil use from childhood 
to adulthood and other relevant age-specific information using a validated 
questionnaire (EnvIMS-Q). The association between exposure to vitamin D through 
cod liver oil use at different ages and MS risk was estimated as odds ratio (OR) and 
95% confidence intervals (CI) using logistic regression. Apart from age and sex, we 
adjusted the analyses for outdoor activity during the summer, a proxy of sun 
exposure, dietary intake of vitamin D-rich fatty fish, history of mononucleosis, 
smoking, body size during adolescence, education, and MS family history. For the 
second and third objectives, we conducted population-based nested case-control 
studies within the historical cohort of all men born in 1950-1995 who underwent the 
mandatory Norwegian conscription examination at age 18-19 (about 90% of all 
Norwegian men). We identified men who went on to develop MS later in life through 
linkage of the Conscript Service Database to the Norwegian MS registry and selected 
controls randomly from the same database frequency-matched on year of birth to all 
the cases in the MS registry. For article 2, we included 924 men who later developed 
MS and 19,530 controls with information on cognitive performance at conscription. 
We compared their cognitive scores (standard nine scale, mean=5, standard deviation 
(SD)=2), standardized on 5-year birth cohorts, overall and according to initial disease 
course, relapsing-remitting (RRMS) and primary progressive MS (PPMS), using 
Student’s t-test. We also assessed the risk of MS in the years following conscription 
among men who scored lowest (>1 SD below the controls’ mean) compared to the 
rest using Cox regression to estimate relative risk (RR) and 95% CI. For article 3, we 
included 854 men who later developed MS and 14,563 controls, all born in 1950-
1975, with information on a) weight and height, from which we determined body 
mass index (BMI), and on b) physical fitness test result (score on standard nine 
scale). We estimated the independent effect of BMI, as a measure of body size, and 
fitness, as a measure of regular vigorous exercise, at age 19 and MS risk later in life 
using Cox regression and reported RR and 95% CI.  
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Results: In article 1, we found that cod liver oil use during adolescence was 
significantly associated with a decreased MS risk compared to no supplementation 
during adolescence (OR=0.67, 95% CI: 0.52-0.86), whereas there was no association 
between use reported during childhood or adulthood. The estimates were mutually 
adjusted for each other and did not materially change after adjustment for other 
potential confounders. A dose-response relationship was suggested between higher 
cod liver oil doses during adolescence and lower MS risk peaking at 600-800 
international units/ day of vitamin D consumed through cod liver oil (OR=0.46, 95% 
CI: 0.31-0.70, p trend=0.001). In article 2, we found that only men who developed 
MS within 2 years after conscription scored cognitively significantly lower at age 18-
19 than controls, equivalent to 6 IQ-points. There was, however, no overall difference 
in cognitive scores between the comparison groups. Results were similar when we 
assessed men who went on to develop RRMS, while men who went on to develop 
PPMS scored significantly lower than controls at that age, by an equivalent of 4.6-6.9 
IQ-points, although they would not develop first symptoms up to 20 years later. Men 
who scored lowest had an increased RRMS risk within 2 years from conscription 
(RR=2.69, 95% CI: 1.41-5.16), and an increased PPMS risk within 20 years. Finally, 
in article 3, we found that higher BMI (≥25kg/m2) was associated with higher MS 
risk (RR=1.36, 95% CI: 1.05-1.76) compared to normal BMI, and that higher aerobic 
fitness was independently associated with lower MS risk (RR=0.69, 95% CI: 0.55-
0.88, p trend=0.003).  
Conclusions: The findings of this thesis add to the evidence linking low vitamin D to 
MS risk and further point to adolescence as the crucial postnatal period, in which 
adequate levels should be ensured. Further, these findings suggest that MS has a 
prodromal phase with subtle but detectable signs. RRMS could start years prior to 
first relapse, while PPMS could potentially start decades prior to onset of progressive 
symptoms. Lastly, these findings add weight to evidence linking being overweight to 
MS risk among men and suggest, further, that vigorous exercise or a factor strongly 
associated with high cardiorespiratory fitness may be an additional modifiable 
protective factor for MS that warrants further investigations. 
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The aim of medicine is to prevent disease and prolong life, the ideal of medicine is to 
eliminate the need of a physician. 
William James Mayo (1928)  




1.1. Multiple sclerosis- an overview 
Multiple sclerosis (MS) is a chronic immune-mediated neurologic disorder of the 
central nervous system (CNS) and can lead to severe disability.1 It is thought to 
develop in genetically predisposing individuals under the additional influence of 
environmental triggers.1 The underlying causes are, however, ultimately unknown.2 
The socioeconomic burden of MS is high as it commonly afflicts young adults and is 
one of the most common disability causes in this group.3 The disease course is 
difficult to predict, as MS is heterogeneous on the radiological, clinical, and 
pathological level.4-6 Patients are thus faced with a chronic unpredictable disease in a 
stage of life in which they are establishing themselves privately and professionally.3 
MS reduces life expectancy moderately (7-14 years),7 and most recent studies report 
improved survival over the last decades.8 However, high morbidity due to MS and 
comorbid conditions markedly reduce quality of life,9 in part mediated through 
alteration of employment status.10, 11 While disease-modifying treatment can be 
offered to many though not all patients, MS remains a feared disease, so far without 
any curative treatment.12-14 
 
 
1.2. Occurrence and distribution 
It is estimated that about 2.3 million individuals worldwide suffer from MS with 
substantial geographical differences in incidence rates and prevalence.15 This updated 
estimation from a recent survey suggests that the global burden of MS has been 
increasing in prevalence from 2008 to 2013 by about 9%.16 The median global 
prevalence was estimated at 30 in 2008 and 33 in 2013 per 100 000 individuals, 
including high-risk areas like North-America and Europe (>100 per 100,000) to low-
risk areas including Central America, Sub-Saharan Africa and East Asia (≤5 per 
100,000) (Figure 1).16 Kurtzke’s once suggested geographical MS distribution into 
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three zones of high, medium and low frequency (>30, 5-25, <5 per 100,000) seems 
therefore still applicable.17 The prevalence of MS is determined by disease incidence, 
detection, and duration and it is unclear to which extent the higher MS burden is due 
to an increase in disease frequency, awareness, reporting, diagnosis, or prolonged 
patient survival.18 Studying incidence rates may be more insightful in this respect.  
 
Figure 1: The prevalence of multiple sclerosis in 2013 by country. 
Reprinted by permission from the Multiple Sclerosis International Federation: The Atlas of 
MS 2013 report, page 8,16 https://www.msif.org/about-us/who-we-are-and-what-we-
do/advocacy/atlas/, © Copyright 2013 
The median MS incidence is estimated globally at 5.2 per 100,000 per year during the 
last decades with substantial regional variation ranging from 0.5 in Panama to 20.6 in 
Alberta, Canada.19 The lowest annual incidence rates were reported for Central 
American, Caribbean, North African, and East Asian countries, while the highest 
rates were seen in the US and Canada followed by most European countries and 
Australia.20-25 Interestingly, disease occurrence has been associated with latitude 
implying that MS is more frequent in areas further away from the equator.26, 27 
However, a recent systematic review of incidence studies published over several 
decades suggests that the latitude gradient is disappearing due to increased disease 
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occurrence in lower latitudes.28 Ethnic differences in incidence rates, with blacks, 
Hispanics, and Asians traditionally considered low-risk groups,29 may be leveling out 
as well, with rates among black individuals similar to or surpassing those among 
white individuals.30, 31 The underlying causes of these changes are unclear.32  
The lifetime risk of MS is about 1 in 200 to 400 in high-risk areas depending on 
sex.33, 34 MS affects more commonly women than men with a ratio of about 2:1 to 
3:1,35 potentially due to an increased female susceptibility to certain risk factors.36, 37 
Recent findings suggest a further divergence between the incidence rates among 
males and females, especially in the most northern latitudes.38, 39 This could either be 
due to an increased MS incidence among women, or a reduced incidence among men, 
or a combination of both. Many studies support the idea that there has been a genuine 
increase in disease occurrence among women.35, 40 In addition, there is some evidence 
that this trend might be, at least partially, related to changes in habits of smoking,41 a 
risk factor for MS.42 A decline in smoking rates the last decades has been more 
marked in men and this could contribute to relatively higher MS rates in women.41 
Norway is among the countries with highest MS prevalence (203 per 100,000) and 
annual incidence rate (8.0 per 100,000).43 While Swank reported lower MS rates in 
coastal regions and higher ones inland in the 1950ies,44 rates are comparable in 
different regions today and there is no latitude gradient within the country.43, 45 A 
four-fold increase in incidence over six decades has been reported regionally, but the 
trend has more recently been stabilizing along with the increase in sex-ratio.46, 47 
Differences by latitude and sex gave rise to hypotheses regarding MS etiology. 
Exposures like ethnicity, vitamin D and sun exposure, diet, infectious agents, and 
hormonal triggers became hereby of interest.48 
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1.3. Disease presentation  
1.3.1 Clinical and radiological features 
The incidence of MS increases during adolescence with very few cases manifesting 
during childhood.49, 50 About 80% of MS patients experience clinical onset at ages 20 
to 50 years.51 The two initial core MS phenotypes are relapsing-remitting (RRMS) 
and primary progressive MS (PPMS) (Figure 2),5 and RRMS is the most common 
form comprising about 85% of all cases.52 Affected individuals experience a sudden 
clinical MS onset peaking around age 30, characterized by an acute episode with 
neurological deficits (relapse) due to focal inflammatory processes in the CNS,53 but 
remission of function usually follows the more or less frequent relapses in RRMS.54 
RRMS presents commonly with motor, visual, sensory, or brain stem related 
functional deficits,1, 55 Most RRMS patients eventually enter a progressive stage, 
secondary progressive MS (SPMS),56 with gradual irreversible deterioration due to 
neurodegenerative processes possibly with superimposed relapses after a median of 
15 to 20 years, as observed in mainly untreated patients.57-61  
 
Figure 2: The clinical phenotypes of multiple sclerosis. 
The figure shows the MS phenotypes Clinically isolated syndrome, Relapsing-remitting, 
Secondary progressive, and Primary progressive MS with mean onset age and disability 
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resulting from inflammation and degeneration in the CNS. It also implies sub-clinical MS, 
disease activity below the clinical threshold, prior to first specific neurologic symptoms. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology 15: 
546,62 http://www.nature.com/nri/index.html, © Copyright 2015 
Individuals developing the less frequent form, PPMS, affecting about 15% of all 
cases, usually experience a less acute, more insidious clinical onset with the first 
neurologic symptoms at a median age of 40 years, as illustrated in Figure 2.52 This 
phenotype is characterized by neuronal degeneration and accumulation of irreversible 
functional deficits over time.63 PPMS manifests for most cases as spastic 
paraparesis.64 While RRMS is more frequent among women with an incidence ratio 
of about 1:2 to 1:3, PPMS affects men and women more or less equally.47, 65 
Today, decades after an expert panel agreed on the first diagnostic criteria in a time 
before magnetic resonance imaging (MRI) became available,66 MS remains a mainly 
clinical diagnosis made retrospectively.5, 67 It is based on the detection of 
dissemination in time and space of clinical CNS involvement, explicitly proposed by 
Schumacher and colleagues in 1965.68 Diagnostic criteria of PPMS were only 
specified in 2000.64 However, MRI is today incorporated into the diagnostic process. 
The simultaneous presence of gadolinium (Gd)-enhancing and non-enhancing 
asymptomatic lesions on the first scan indicates dissemination in time as well as 
space, and allows the diagnosis of clinically definite RRMS after only one clinical 
event.67, 69 MRI has helped to decrease diagnostic uncertainty in early MS and shorten 
the time from manifest disease to diagnosis.70 Identifying predictors of conversion to 
definite MS after a single clinical event suggestive of MS contributed to these 
developments.71  
Clinical parameters are also important to assess the MS course.5 While relapses are a 
sign of active disease, a higher Expanded Disability Status Scale (EDSS) score 
indicates worsening or progression, especially when confirmed with reasonable time 
apart.5, 72 EDSS is a score ranging from 0 (normal) to 10 (death due to MS) given 
based on a thorough neurologic evaluation of different functional systems, with 
important landmarks like an EDSS of 7 indicating restriction to wheelchair.72 
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Cognitive impairment, which is frequent in MS, seems to most commonly affect 
patients with PP- and SPMS and is thus also considered a clinical sign of progressive 
disease.73 It is better captured by validated neuropsychological tests than EDSS,73, 74 
including sensitive clinical measures for the most common cognitive deficit in MS, 
i.e. slowing of processing speed.75, 76 The radiological measures of disease activity 
and progression include Gd-enhancing T1-, new/enlarging T2-weighted MRI lesions 
on the one hand and brain volume loss on the other.77-80 A newer ambitious outcome 
measure, “no evidence of disease activity” (NEDA), is a composite score of clinical 
and radiological freedom from MS activity and progression as a treatment response to 
potent disease-modifying agents aiming at long-term remission.81-83  
In spite of these measures, predicting conversion and progression remains, however, 
challenging.84-86 In RRMS higher initial relapse rate, shorter time elapsed to the 
second clinical episode, and higher EDSS several years after onset have been 
suggested to be negative prognostic factors.53, 84 Relapses appear to be more 
predictive of short-term progression, especially in younger patients.87, 88 In PPMS a 
fast initial disability accumulation speed has been associated with worse prognosis.84  
1.3.2 Pathogenetic mechanisms 
In MS, immunological processes fuel pathological changes manifesting as either 
neuronal inflammation or degeneration.62 An imbalance between pro- and anti-
inflammatory cellular and humoral immune components plays an important role in 
initiating and sustaining a cascade of pathognomonic processes, although the triggers 
and chronology of events are not entirely understood.1 The immune system is 
probably directed against the myelin sheath that facilitates saltatory propagation of 
nerve impulses to the target organ and is important for the homeostasis of the 
neuron.62  
Autoreactive CD4+ T-lymphocytes, insufficiently inhibited by CD4+ regulatory T 
(Treg)-lymphocytes,89-91 can differentiate to neurotoxic T helper (TH) cells type 1 and 
17 and cross the blood-brain barrier.92 They play a central role in promoting and 
perpetuating, along with activated CNS-resident microglia and astrocytes, 
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inflammation and demyelination targeting oligodendrocytes, the cells that build the 
myelin sheath.92-94 Monocytes and other antigen-presenting cells are recruited and 
produce pro-inflammatory neurotoxic and chemotactic cytokines potentiating the 
immune response.95, 96 B-lymphocytes, activated to complement-producing plasma 
cells, are also involved in the immune response.97 They produce oligoclonal 
antibodies that have been of diagnostic and prognostic value, and might target myelin 
proteins, though it is unclear which antigens specifically.67, 98, 99 The loss of the 
isolating protective myelin sheath leads to functional deficits due to disturbed electric 
impulse propagation94, 100 and to axonal transection.101, 102 However, at an early stage 
compensatory mechanisms like re-myelination can restitute the neuro-axonal integrity 
and function.103, 104 Focal inflammation and demyelination is prominent in RRMS,105 
leading to the typical multifocal periventricular, infra-tentorial, and spinal lesions in 
the white matter, rich in CD4+ TH17- and CD8+ T-cell infiltrates if acute.93  
Inflammation and demyelination are also present in PPMS and SPMS, although 
typically in a more diffuse pattern, even within normal-appearing white matter.63, 105, 
106 Cortical lesions are a hallmark of progressive disease105 and seem to correlate 
more strongly with physical and cognitive disability.107 These lesions may explain, to 
some degree, the discordance between white matter lesion location/extent and clinical 
symptoms known as clinico-radiological paradox.108 Neurodegenerative processes are 
associated with more CNS-intrinsic chronic inflammation sustained by chronically 
activated microglia and astrocytes and potentiated by exhaustion of compensatory 
mechanisms.62, 109 Chronic inflammation favors the formation of reactive oxygen 
species provoking mitochondrial injury and hence energy inefficiency, metabolic 
stress, and ionic imbalance, detrimental to the neuron.110 Accumulating irreversible 
neuro-axonal loss leads to brain volume loss that is associated with disability.111, 112  
While these changes are present from clinical onset in PPMS, they indicate 
progressive disease in RRMS. Still, there is no clear cutoff for the onset of SPMS and 
neurodegenerative processes may evolve as a continuum from early MS.113  
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1.3.3 Points of debate 
The distinction of two core initial disease courses114 animated a discussion on 
whether RRMS and PPMS are phenotypes of the same disease or distinct diseases,115 
further highlighting the complexity of MS. Genetic,116 clinical,117 and pathological 
evidence105 argue against, and the inconsistent immunological evidence not 
compellingly for fundamentally different diseases.118-121 Differences between 
relapsing and progressive MS are thus probably rather quantitative than qualitative.115 
PP- and SPMS share core characteristics like higher onset age, progressive character, 
and speed of disability accumulation. The spinal and cortical lesion load is also 
comparable.105 PPMS may thus be MS “amputated” from the relapsing stage.122 RR- 
and PPMS are today rather considered two phenotypes of the same disease.5, 63, 122  
Despite an ongoing quest for prognostic factors, evidence suggests that MS 
progression and the speed of disability accumulation is dependent on age and not on 
initial clinical features,51, 88, 117, 122-125 explaining maybe the difficulties in predicting 
progression. This means that disability milestones are commonly reached at a certain 
age rather than after a certain time from clinical onset.117 Individuals with disease 
onset later in life will reach disability milestones faster than those with earlier onset. 
This seems to also apply to pediatric onset MS patients who, interestingly almost 
exclusively, develop relapsing disease.126  
Whether focal inflammation in the CNS triggers neuronal degeneration or whether 
both are mutually independent processes manifesting simultaneously but in an 
opposed waxing and waning manner has long been debated in MS.63 How exactly 
diffuse inflammation and re-myelination affect this interplay is also unresolved.1, 63 
The first disease-modifying drugs for MS were approved in the early 1990s and 
several more potent ones followed over the years.127-131 These drugs were shown to 
reduce (focal) inflammatory MS activity.132 However, it is not entirely clear how 
effectively they delay neuronal degeneration and hereby disability progression,133, 134 
as they proved ineffective for PPMS (with the exception of one agent approved 
recently135) and SPMS.136, 137 Brain volume decrease seems unaffected138 and 
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evidence on preservation of cognitive function is inconclusive.139 Still, early 
treatment to slow progression is advocated by many studies, but their relatively short 
follow-up time may not reflect long-term outcomes.140 Confavreux and colleagues 
suggested that inflammatory and degenerative processes proceed independently from 
onset because of the low effect of modifying drugs on long-term irreversible 
disability accrual and cerebral atrophy, despite potent immunosuppression.88 On the 
other hand, Leray et al. suggested MS to be a two-staged disorder, in which the 
progressive stage does not depend on events in the initial stage.141 Prognostic factors 
like relapse rate may predict worsening and duration of the first stage but not be able 
to predict progression and disability in more chronic disease. There is some 
agreement on that once processes pertaining to progressive disease are set in motion, 
they run independently from inflammatory disease components.63, 142  
Knowledge on these aspects was gained in population-based cohorts of treatment-
naïve MS patients with a long follow-up, ideal to study the natural MS history.143 
They help us understand the MS evolution and course, facilitate prognostic 
considerations, treatment decisions, and inform the design/interpretation of clinical 
trials.84, 144-146 However, it has been more difficult to learn about prodromal MS, and 
identify when MS starts, which could also facilitate the search for causal factors.147 In 
most studies, date of first symptom(s) has been used to define MS onset. 
 
1.4. Evidence of prodromal multiple sclerosis 
1.4.1 Clinically isolated syndrome 
Clinically isolated syndrome (CIS) is the first clinical presentation of focal 
inflammatory CNS demyelination suggestive of MS and is part of the MS phenotype 
spectrum (Figure 2).5, 148 An individual with CIS can be diagnosed with MS at a 
second independent relapse or if MRI shows dissemination in time according to 
current diagnostic criteria, as described above.67 Conversion rates to definite MS 
depend on length of follow-up but vary markedly between CIS patients with normal 
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(20-25%) and abnormal (70-80%) MRI scans over the course of 15-20 years.149, 150 
Early treatment initiation delayed conversion in different clinical trials.151-153  
CIS marks the time, at which previously subclinical MS exceeds the clinical 
threshold and becomes apparent (Figure 2).1 Indeed, CIS can be associated with signs 
of long-lasting disease processes. A high lesion burden on the first MRI scan,71 
including old inactive lesions, and fatigue154 are common among CIS patients and 
predict conversion. Further, cognitive impairment may be similarly prevalent among 
CIS and RRMS patients, although it was traditionally considered a late symptom 
associated with progression.73, 155, 156 Presence of cognitive impairment has also been 
suggested to predict conversion to clinically definite MS.157 Even brain atrophy, a 
correlate of neuronal degeneration, can be present at first clinical presentation.158, 159 
What triggers the clinical MS onset is unknown. 
1.4.2 Radiologically isolated syndrome 
The radiologically isolated syndrome (RIS) can be a sign of MS activity prior to 
clinical onset.160 Individuals with RIS are detected by coincidence when a brain MRI, 
performed for other reasons than suspicion of MS, reveals lesions in an MS-typical 
pattern.161 The existence of clinically silent MS was suggested as early as in the 
1960s based on autopsy findings.162 Depending on the study, 30-45% convert to CIS 
over the course of 2 to 5 years,163 and spinal cord in addition to brain lesions are a 
strong predictor of conversion to CIS/RRMS or PPMS.164, 165 RIS patients usually 
remain untreated due to the absence of specific neurologic symptoms suggestive of 
MS.166 Interestingly, at closer examination they may display cognitive impairment,167-
169 fatigue,170, 171 and brain volume changes172, 173 to a similar extent as CIS and MS 
patients. RIS can be detected many years prior to the clinical MS onset according to 
case reports,174 but time of true disease onset is unknown. 
1.4.3 The neuroepidemiological challenge 
It can be challenging to study the causes of diseases with a long prodromal phase, like 
neurodegenerative disorders including Alzheimer’s and Parkinson’s disease (PD).175, 
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176 Even though there is agreement that MS also starts prior to clinical presentation, 
discussed as early as in 1965 by Kurtzke,177 the duration and nature of prodromal MS 
activity are largely unknown beyond knowledge about RIS.178, 179 If knowledge about 
the onset of a disease is limited, the Hill criterion of temporality that is essential 
(though not sufficient) to evaluate whether an association is more likely to be causal 
in observational studies, might be violated.180 The cause needs to precede the effect 
but an incorrect conclusion about the putative cause-effect direction is possible if a 
yet undetected sub-clinically active disease leads to changes in behavior, biological 
parameters, or proneness to certain events.181, 182 This needs to especially be assessed 
for new putative risk factors. The association between head trauma and PD risk 
illustrates the problem of reverse causation potentially underlying an association.175 
Whether head trauma is a cause of PD or incipient postural instability in a yet 
unidentified PD patient increases the risk of falls and thus head injury, is difficult to 
decipher.175 Further, the distinction between classic causes and triggers adds to the 
complexity, as additional triggers might be necessary during the latent period for the 
disease to manifest altogether or at an earlier time, potentially providing a window of 
opportunity for intervention.18, 178 Moreover, knowledge about the true disease onset 
can facilitate the detection of susceptibility periods for important exposures (see next 
section).18 All in all, knowledge about latency periods is difficult to gain 
prospectively.178 Studies on RIS are valuable but are not prospective regarding 
prodromal MS, as these individuals are already aware of a potential disease. RIS 
patients might, further, not be representative of all prodromal MS patients. 
 
1.5. Etiology 
MS is likely caused by a combined effect of genetic and environmental factors.1 As 
so far known, positive family history of MS is the strongest predictor.183 Studies on 
familial risk assessing different degrees of kinship between MS patients and their 
relatives suggest that genetic predisposition increases with the proportion of shared 
genes (Figure 3).184, 185 MS concordance is about 25% among monozygotic twins and 
about 1% among cousins, which is still 3-5 times higher than the lifetime MS risk in 
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the normal population.186-188 Alleles coding human leukocyte antigen complex (HLA) 
class II cell surface proteins involved in antigen-presentation on immune cells convey 
the highest risk,189-191 especially HLA-DRB1*1501,192 but there are also protective 
genotypes, HLA-A*02 (HLA class I).193 Genome-wide association studies have 
revealed further independent susceptibility genes, single nucleotide polymorphisms, 
and mutations in immunologically relevant genes involved in MS.194, 195 
 
Figure 3: Recurrence risk of multiple sclerosis within families. 
The figure shows the lifetime risk of individuals with positive family history of multiple 
sclerosis according to degree of kinship. Reprinted by permission from Elsevier: The Lancet 
372: 1506,1 http://www.thelancet.com/, © Copyright 2008 
Although these findings support that genetic factors are crucial, the incomplete 
concordance among identical twins and implication of immune-regulating genes also 
involved in other autoimmune diseases and altogether explaining not more than 30% 
of the risk, indicate, at the same time, a major role of the environment.62 Findings 
from migration and space-time cluster studies and incidence trends over the last 
decades provide further evidence for an important environmental influence.27, 196 
Gene-environment interaction studies try to integrate both components and explain 
MS risk more comprehensively,197, 198 and epigenetic mechanisms may underlie these 
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interactions.199 However, it is clear that some major undiscovered determinant(s) are 
likely involved to more comprehensively portray the picture of MS susceptibility. 
 
1.6. Environmental risk factors and susceptibility periods 
The environmental factors most consistently associated with the risk of developing 
MS are Epstein-Barr virus (EBV) infection, low vitamin D levels, tobacco smoking, 
and obesity in early life.32, 200 Evidence is most consistent for RRMS and there is a 
lack of studies focusing on PPMS.201 An involvement of modifiable factors in the 
etiology of MS represents an opportunity, as prevention of MS can be regarded as the 
highest potentially achievable goal provided that evidence from different fields 
converges.32, 48 Studies on the population attributable risk of potential factors are 
theoretical examples of that approach.202, 203 
To strive for this goal, apart from identifying relevant exposures, it is essential to 
determine when these influence MS susceptibility.196 Migration studies gave some 
clues about the timing of environmental exposures suggesting that an individual’s MS 
risk is determined during the first two decades of life.204 Individuals migrating from 
high- to low-risk areas showed disease rates similar to those at their destination only 
if they moved before age 15, but retained the higher risk of their country of origin if 
migrating after that age.205, 206 Further studies hinted to a continuous risk decrease 
with earlier age at migration.207, 208 The fact that MS risk in the host country is not 
entirely adopted after migration could be due to genetic predisposition linked to 
ethnicity or a susceptibility period in utero.209-211 Studies of individuals migrating 
from low- to high-risk areas indicate an inverse trend, but were based on very small 
samples.212 Space-time cluster studies provided further clues for a critical age at 
which environmental factors act, reporting a statistically significant clustering of 
cases during early life.213, 214  
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1.6.1 Epstein-Barr virus 
Infectious agents have long been suspected to play a role in MS with major attempts 
to explain the nature of their involvement.215 The hygiene hypothesis for MS evolved 
in the 1960s after Poskanzer proposed that MS could be a rare consequence of an 
infection contracted at higher age in areas further away from the equator due to better 
sanitary conditions. 216 He compared it to clinical poliomyelitis, which was common 
in regions with better and rare in regions with worse sanitation, where the poliovirus 
was ubiquitous from childhood. For the first time, age at exposure was suggested to 
modify MS risk.217 An early exposure to various infectious agents, which is more 
common in regions with poor hygiene, was later suggested to be important for the 
development of an immune response away from a pro-inflammatory TH1- to a more 
Treg- and TH2-cell milieu.218 Reports of MS epidemics after local deployment of 
foreign soldiers on the Faroe Islands, where MS had previously not been observed, 
prompted Kurtzke in the 1990s to another hypothesis.219 A contagious infectious 
agent more prevalent away from the equator may lead to an asymptomatic infection 
in most, and occasionally to MS in some individuals years later. These hypotheses 
initiated a search for an infectious MS cause, which is still ongoing today.215, 220 
However, so far only the herpes virus EBV, first suggested in 1981 as a potential 
candidate,221 has consistently been related to MS.215 
Striking similarities have been noted between the epidemiology of MS and 
symptomatic EBV infection, referred to as infectious mononucleosis, which is more 
common when EBV is contracted later in life, during adolescence or adulthood.221 
The EBV-seroprevalence is about 95% by adulthood,215 but a latitude gradient, 
inverse to that observed for MS distribution, was noted for EBV-antibody prevalence 
during childhood with a higher share of seropositive individuals in (sub)tropical 
(developing) regions and a lower one in more temperate (developed) regions.222 In 
areas with poorer hygienic conditions EBV is most often acquired asymptomatically 
during childhood, whereas in more affluent areas many individuals remain uninfected 
up to adolescence, when the exposure likelihood to EBV in saliva increases again 
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substantially.200 Infectious mononucleosis is thus considered a marker of high 
hygienic conditions during childhood. 
The evidence suggesting that EBV is involved in MS etiology is compelling and MS 
could be considered a rare complication of an EBV infection.200 Findings from 
prospective studies support a strong monotonic relationship between elevated EBV-
specific serum antibody titers, especially IgG against Epstein-Barr nuclear antigens 
(EBNA), and MS risk.223-227 Individuals with late primary infection resulting in 
mononucleosis were at 2.3 times higher and EBV-negative individuals at about 15 
times lower risk of MS compared to individuals acquiring EBV during 
childhood/without mononucleosis history (Figure 4).200, 228 A prospective study 
among US military personnel also found that EBV-negative individuals can 
practically not develop MS and importantly, observed, that all EBV-negative 
individuals who later developed MS seroconverted several years prior to clinical MS 
onset.229 According to the hygiene hypothesis seronegative individuals ought to have 
the highest MS risk, but they appear to, instead, have a very low MS risk. These 
studies seem thus to suggest a more direct EBV involvement in MS pathogenesis 
rather than reflecting the hygiene hypothesis.215 
 
Figure 4: Epstein-Barr virus infection and multiple sclerosis risk. 
The figure shows the relative risk (RR) of MS for EBV-negative individuals and individuals 
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who had infectious mononucleosis compared to EBV-positive individuals without history of 
mononucleosis (Ref) and the corresponding p-values. Reprinted by permission from Georg 
Thieme Verlag KG: Seminars in Neurology 36(2): 108,200 http://www.thieme.com/books-
main/neurology/product/2163-seminars-in-neurology, © Copyright 2016  
The mechanisms underlying this strong association remain unresolved.200 Direct CNS 
infection has been proposed, but the findings are overall inconsistent and the virus 
has not consistently been detected in the CNS.230-234 Trials on antiviral treatment of 
MS patients were not successful, although this cannot exclude that EBV could initiate 
MS.235, 236 The immune response to EBV could also induce cross-reactivity to self-
antigens (molecular mimicry).237-239 These mechanisms need to be elucidated before 
EBV can be seen as a modifiable factor for MS, supporting approaches like early 
intentional infection to prevent mononucleosis or the development of a vaccine.200  
1.6.2 Vitamin D 
Exposure to sunlight is the major vitamin D source.181 Cholecalciferol (vitamin D3) is 
synthesized in the skin with the aid of ultraviolet B rays (Figure 5).240 With higher 
latitude the sun dose decreases and cholecalciferol intake through diet (fatty fish, 
fortified foods) and supplements (vitamins, cod liver oil) gains relatively in 
importance, especially during winter,181 when the sun-induced production diminishes 
considerably (36-43°, Spain) or ceases completely (58-71°, Norway).241 Apart from 
geographical, seasonal, and phenotypical factors (e.g. skin tone), sun-avoidance is an 
important reason for the worldwide common vitamin D deficiency.242, 243  
In the liver cholecalciferol is enzymatically converted to 25-hydroxyvitamin D 
(25(OH)D), the most commonly used serological marker of vitamin D status (Figure 
5).181 Through further hydroxylation in the kidney, 25(OH)D is converted to the 
hormonally active metabolite, calcitriol (1,25-dihydroxyvitamin D), that can bind to 
vitamin D receptors in the nucleus and on the plasma membrane, affecting gene 
expression by functioning as transcription factor and signal transduction.244 
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Figure 5: Vitamin D metabolism in humans. 
The figure shows the sources, the metabolism, and the bioavailability of vitamin D. 
Reprinted by permission from Elsevier: The Lancet Neurology 9: 600,181 
http://www.thelancet.com/journals/laneur/issue/current, © Copyright 2010 
Vitamin D deficiency was first discussed as a potential factor in MS etiology in the 
1970s,245 supported by an observed link between geography, sunlight exposure, diet, 
and MS prevalence in ecological studies.44, 246, 247 Today there is converging evidence 
to support the vitamin D hypothesis, including four major prospective studies (three 
are illustrated in Figure 6).200 Munger et al. examined data from two large cohorts and 
found that women reporting an intake of >400 international units (IU) of vitamin D 
from multivitamins had an about 40% lower MS risk.248 The same group reported that 
vitamin D levels >98nmol/l, as measured in blood samples from military personnel 
were associated with an about 60% lower MS risk compared to levels <63nmol/l.249 
The association was most marked for intake during adolescence and modified by 
ethnicity. Salzer and colleagues, an independent group, reported a decrease in MS 
risk of similar magnitude when comparing levels of 75 and higher to levels below 
75nmol/l.250 Further support for the vitamin D hypothesis comes from recent findings 
in a prospective study within the Finnish Maternity Cohort including serum samples 
from about 1000 cases and 2000 controls. Vitamin D deficient women (<30nmol/l) 
had a 43% higher MS risk compared to women with levels ≥50nmol/l.251 These 
prospective findings substantiate the validity of the results from different case-control 
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studies suggesting a protective effect of vitamin D.252-256 An intrinsic beneficial effect 
of sunlight not mediated through vitamin D was proposed in a study assessing 
specifically outdoor-activity independent of vitamin D status.257 Still, there is 
otherwise little evidence to support a purely independent mechanism, especially 
given positive results from diet studies.248, 252 Recently, the results of Mendelian 
randomization studies using genetic predictors of vitamin D levels as an instrumental 
variable, argued against confounding bias underlying the association between low 
vitamin D and MS risk and provides thus, so far, the most causally interpretable 
evidence.258, 259 Whether vitamin D modifies disease activity is not completely 
resolved.260 Vitamin D supplementation trials for MS management, although 
alleviating safety concerns, are so far inconclusive regarding an effect, potentially 
due to small sample sizes,261-263 but further trials are underway.264 
 
Figure 6: Multiple sclerosis risk in three major prospective studies on vitamin D. 
The figure shows the relative risk of MS for exposure to vitamin D comparing supplemental 
intake of ≥400 international units (IU)/ day (d) versus none, serum levels of ≥99 to 
<63nmol/l, and >75 to ≤75nmol/l. Reprinted by permission from Georg Thieme Verlag KG: 
Seminars in Neurology 36(2): 104,200 http://www.thieme.com/books-
main/neurology/product/2163-seminars-in-neurology, © Copyright 2016  
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The immune-modulatory properties of vitamin D may be mediated through the 
vitamin D and the interleukin (IL)-10 receptor,265, 266 and potentially result in a 
promotion of the Treg-cell function,267 as well as a range of other anti-inflammatory 
effects.260 Experimental studies suggest a disease-preventive and -modulating effect 
of calcitriol in experimental autoimmune encephalomyelitis (EAE),268, 269 a 
commonly used MS mouse model, but prevention seemed to be limited to female 
animals when administering cholecalciferol.266, 270  
At which age an adequate vitamin D level is most important or whether cumulative 
exposure matters is not entirely understood.196 For the design of future trials and 
potential implementation of public health measures knowledge about optimal timing 
of interventions is important.260 Different age periods have been suggested254, 255, 271, 
272 and the prenatal phase might represent an independent susceptibility period.209-211 
No study compared all postnatal periods systematically and prospective studies are 
often underpowered to investigate timing of environmental factors in detail.249, 272 
1.6.3 Tobacco smoking 
The evidence suggesting a detrimental effect of smoking on MS risk is strong and 
comes from prospective,273-275, retrospective,203, 276-279 cross-sectional,280 and 
biomarker data.37, 281 Most of the reported effect estimates indicate a 1.4-1.8 times 
higher risk among exposed individuals and a dose-dependent effect between self-
reported smoking and MS, with increasing risk in the order passive, ever, light, and 
heavy, compared to never smokers.282 Elevated cotinine levels, a biomarker of current 
smoking, have also been linked to an increased MS risk, and the association was most 
pronounced for exposed individuals who were younger at blood sampling,281 
suggesting that smoking in early life might be the relevant exposure.283 In a small 
investigation on gestational exposure the authors found, however, no link to MS.283 In 
recent meta-analyses, the effect on MS risk was estimated to be about 1.5 among ever 
compared to never smokers, with a significantly higher risk in men as to women.284  
Which of the compounds in smoke might adversely affect MS susceptibility is not 
clear, but a systemic immunologic effect seems likely considering that smoking has 
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been associated with increased risk of different autoimmune diseases like rheumatoid 
arthritis or systemic lupus erythematosus.285 Chewing tobacco and snuff use was not 
related to an increased risk of MS. Snuffing was instead surprisingly associated with 
a decreased risk, and a neuro-protective effect of nicotine was proposed.277, 286, 287 
These studies indicate that combustion metabolites or lung-specific mechanisms may 
be involved in altering the immune response. Interestingly, a passage through the 
lungs seems to be important for peripheral T-cells to acquire the ability to migrate 
across the blood brain barrier and induce autoimmune processes.288 The effect might 
also be, partially, mediated through vitamin D as smoking is associated with lower 
levels.289 Further studies on a potential interaction with other genetic and 
environmental factors for MS might help revealing underlying mechanisms and 
deserve further investigation.290 
1.6.4 Obesity 
Overweight has been linked to MS risk in both prospective291-293 and retrospective294-
296 studies using body mass index (BMI) or validated figure rating scales as measure 
of body fat mass.200 A detrimental effect of excess adipose mass has consistently been 
suggested in women, while associations are more inconsistent and suggest a weaker 
effect in men.200 Further investigations are needed to elucidate these discrepancies. 
The first longitudinal study found a significant 1.4 and 2.3 times higher MS risk, for 
women who reported being overweight (BMI 25-<30kg/m2) or obese (BMI 
≥30kg/m2) at age 18 respectively, according to the definition of the World Health 
Organization (WHO).293 In a different cohort, the authors found a 1.6-1.9 times 
higher risk of adult-onset MS for girls with a BMI≥95th percentile compared to those 
<85th percentile at age 7-13.292 In boys, the association was weaker and did not reach 
statistical significance. Another prospective study reported a significant association 
between excess body fat mass and pediatric MS, especially among girls that were 12-
18 years old, but no association among boys.291 Several case-control studies followed 
with findings in line with those in prospective studies.294-296 Estimates ranged from 
about 1.5 to 2.0 indicating higher odds of MS among those with excess body fat, with 
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significant results among men and women in two studies295, 296 and only in women in 
the third study.294 Interestingly, a Mendelian randomization study using genetic 
predictors of high BMI as an instrumental variable, reported a 41% increase in MS 
risk for one standard deviation (SD) increase in BMI, corresponding to 4.7kg/m2.297 
No major differences by sex were reported. However, for causal interpretation of an 
association between an instrumental variable and MS, one important assumption that 
needs to be met is that the genetic predictors of BMI influence MS risk only through 
BMI and not independently through other pathways. The presence of pleiotropic 
effects cannot be excluded, especially for complex exposures like BMI.298  
Previous studies point to adolescence as the important period during which excess of 
adipose tissue ought to be avoided to modify MS risk.299 Childhood exposure has also 
been proposed, but body size during childhood correlates with that during 
adolescence, and could thus be a marker of adolescent exposure.293 MS patients may 
experience weight loss after MS onset as suggested in a prospective study, further 
emphasizing the importance of exposure measurement in early life.293 
Two main mechanisms have been proposed to underlie this link. One might be the 
sequestration of vitamin D, a lipophilic compound, into the adipose tissue, resulting 
in lower bioavailability and potentially vitamin D deficiency that could mediate the 
effect.300, 301 The other relates to the low-grade systemic inflammation in obese 
individuals due to the endocrine activity of adipose tissue.302 Adipocytes secrete pro-
inflammatory cytokines like IL-6 and tumor necrosis factor-alpha and specifically 
adipokines like leptin that may induce and worsen EAE and trigger MS.303, 304  
1.6.5 Other factors of interest 
It is important to continue the search for novel, especially modifiable, factors for 
MS.200 Different factors have been proposed, e.g. sodium, caffeine, polyunsaturated 
fatty acids, reproductive factors, and the microbiome, but evidence is limited.200 
There is also interest in the role exercise might play in MS, beyond a neuroprotective 
disease-modulating effect suggested in patients305-310 and EAE.311 However, evidence 
is scarce,312, 313 maybe because capturing exercise as an exposure is challenging. 
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Individuals tend to over-report frequency, intensity, and duration, and objective 
measurements are more costly and difficult to obtain on a large scale.314, 315 In 
addition, prodromal or early MS could lead to decreased exercising and reverse 
causation would then underlie an association between exercise and MS risk.312 
Consequently, the cause-effect direction needs to be assessed cautiously when 
investigating this relationship.  
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2. Study rationale and objectives 
Vitamin D deficiency is among the factors most consistently related to MS risk. 
Although there is indication that this effect varies by age, it is unknown when an 
adequate exposure is crucial to modify MS risk. As MS is a rare disease, detailed 
hypotheses related to timing of relevant exposures are more efficiently assessed in 
case-control studies as these usually include more cases and have thus more power. 
A high BMI has also been linked to MS, but results are only consistent among 
women and whether there is a comparable effect among men is not clear. At the same 
time, there has been interest in the role of physical exercise, whether it is important 
beyond disease modification and might affect MS risk independently of a favorable 
effect on body composition. Putative new etiological factors are best assessed in 
prospective studies, as these are less prone to bias. 
Lastly, while knowledge about RIS supports the idea that MS is active prior to 
clinical onset, prodromal MS is not well characterized. It is unknown when disease 
activity starts prior to clinical MS onset and whether there are subtle signs of this 
activity beyond radiological changes. This might potentially be important for the 
clinical and the research setting. Prospective investigations provide the best evidence, 
but are difficult to conduct. 
Considering these gaps the objectives of the project were: 
a) To investigate the association between postnatal timing of cod liver oil use, an 
important oral vitamin D source in Norway, and MS risk. 
b) To compare cognitive performance of men who later in their life developed 
MS to those who did not, to capture potential differences indicative of disease 
processes prior to first symptom. 
c) To examine the association between BMI and MS risk among men and 
whether fitness, a proxy of exercise, is independently related to disease risk. 
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3. Methods 
3.1 . Article 1- The EnvIMS study 
3.1.1 Data source, study design, and ethical approval 
The multi-national case-control study Environmental Factors In Multiple Sclerosis 
(EnvIMS) was conducted in Canada, Italy, Norway, Sweden, and Serbia, to examine 
environmental risk factors for MS more in detail and potential differences in separate 
populations.316 A self-administered postal questionnaire (EnvIMS-Q, see appendix), 
tested for acceptability, feasibility, and reliability in each involved country, inquired 
about age-specific past exposures such as medical history, dietary, lifestyle, 
occupational, and hormonal factors. The methodological details have been published 
elsewhere.317 The first article of this thesis was based on the Norwegian EnvIMS 
data, with information on supplementation of cod liver oil, an important oral vitamin 
D source in Norway318 that is relatively easy to quantify and recall and has been 
common in the country for several decades.  
The Regional Committee for Medical and Health Research Ethics in Western Norway 
approved the study. Participants received an invitation and information letter and 
gave informed consent by returning the completed questionnaire. 
3.1.2 Study endpoints 
We included 953 MS cases and 1,717 controls in this study. Eligibility criteria for 
participation were an age of at least 18 years and among the cases a disease duration 
of less then 10 years at data collection. Non-responders were contacted with a second 
mailing within 4-6 weeks from the initial invitation to maximize response rates. The 
cases were recruited from the Norwegian MS registry and biobank (described more in 
detail in section 3.2.3).319 The response rate among the 1,368 invited cases was 69.7% 
(women: 72%, men: 64.6%). The controls were randomly selected by Statistics 
Norway from the Norwegian National Registry (Folkeregisteret) including 
information on residents and their time of immigration/emigration, date of birth and 
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death since 1964,320 frequency-matched in a 4:1-ratio on sex and age (within 5-year 
intervals) to the cases. The response rate among the 4,728 invited controls was 36.3% 
(women: 39.4%, men: 29.4%). 
3.1.3 Exposures under investigation and covariates 
We used data on cod liver oil supplementation to estimate intake of vitamin D at 
different ages. One teaspoon (5 ml) of cod liver oil has been the dose recommended 
daily for the past decades by the Norwegian Health Authorities to maintain vitamin D 
levels during the winter months,321 and contains 10 μg (400 IU) of vitamin D, as well 
as omega-3 fatty acids (1.2 g), vitamin A (250 μg), and E (10 mg). Different 
questions explored the supplementation habits. Participants reported their use of cod 
liver oil or capsules as ‘never’ or at ages ‘0-6’, ‘7-12’, ’13-15’, ’16-18’, ’19-24’, and 
’25-30’. The age-scale was adapted to the Norwegian school system to facilitate 
recall. Additionally, more specific questions on quantity, frequency, and seasonality 
were devoted to exposure during adolescence based on previous findings.249 The 
usual serving size (‘no use’, ‘half a teaspoon’, ‘one teaspoon’, ‘half a tablespoon’, 
‘one tablespoon or more’) and supplementation frequency (‘never/ seldom’, ‘1-3 
times/month’, ‘1 time/week’, ‘2-3 times/week’, ‘4-6 times/week’ or ‘7+ times/week’) 
at ages 13-19 both during the winter and the rest of the year were quantified.  
Covariate information on other environmental factors included outdoor activity in the 
summer as a proxy for sun exposure during the same age periods as listed above (’not 
that often’, ’reasonably often’, ’quite often’, ’virtually all the time’), consumption of 
vitamin D-rich fatty fish (herring, mackerel, halibut/flounder, salmon/trout 
respectively) at ages 13-19 (‘never’, ‘1 time/month’, ‘2-3 times/month’, ‘1 
time/week’, ‘2 times/week’, ‘3 and more times/week’) as a proxy of additional 
dietary vitamin D intake, history of infectious mononucleosis (‘yes’, ‘no’, ‘I don’t 
remember’), smoking (never-ever), self-rated body size (silhouette 1-9) in 5-year age 
intervals using Stunkard’s figure rating scale,322 a validated measure of BMI used 
also in a previous study,293 and highest education (elementary, middle, high school, 
college/university, unknown). Further, participants reported family history of MS 
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(affected parent, sibling, or child) and whether they received help to recall past 
exposures (by parents or other person). 
3.1.4 Statistical analyses 
We performed logistic regression in STATA to estimate the effect between timing of 
cod liver oil use and MS risk and reported odds ratios (OR) and 95% confidence 
intervals (CI) at a significance level of 0.05. MS cases were considered exposed if the 
exposure of interest occurred prior to age at disease onset. Controls were considered 
exposed if exposure occurred prior to index age. An index age was randomly 
assigned to each control to match the distribution of onset age among the cases 
making sure that exposure probability was equal among cases and controls.316 
Exposures after MS onset or index age were not considered relevant for our analyses 
(i.e. coded as non-exposed), hereby taking into account clinical disease characteristics 
and that exposures are not equally important throughout life.  
Three age-specific variables were created to investigate the postnatal timing of 
exposure to vitamin D. Exposure to cod liver oil during 1) childhood (ages 0-12) 
compared to no use during childhood, 2) adolescence (ages 13-18) compared to no 
use during adolescence, and 3) adulthood (ages 19-30) compared to no use during 
adulthood. Supplementation during these periods was assessed regardless of use in 
the other periods. The age-specific exposures were first analyzed in (i) separate 
models adjusted for sex and age (6-year categories of year of birth to obtain balanced 
subgroups). Subsequently, all three exposures were included into one model that was 
first adjusted for only age and sex (ii) and then fully (iii).  
The association between vitamin D supplementation during adolescence and MS risk 
was investigated more specifically. From reported frequency and quantity of 
supplementation at ages 13-19, we estimated cod liver oil doses (none, 1-15, 16-30, 
31-45, 46-60, or ≥60 teaspoons/month) and corresponding vitamin D intake (none, 
≤200, 201-400, 401-600, 601-800, or >800 IU/day). The dose-response relationship 
was assessed separately for cod liver oil use during winter and the remaining months.  
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The fully adjusted models included outdoor activity during summer (ages 0-12, 13-
18, 19-30), history of mononucleosis, smoking prior to MS onset, body size at age 15, 
fatty fish consumption at ages 13-19, and education. We also examined whether 
positive family history of MS changed the association in a meaningful way. 
We conducted several secondary analyses. To further increase accuracy we 
reassessed the association between timing of exposure to vitamin D and MS risk 
including only participants into the analysis who received help to recall past 
exposures. Moreover, to assess whether exposure duration mattered beyond timing, 
the association between the continuous supplementation from birth up to different 
ages and MS risk was assessed. Further, fatty fish consumption at ages 13-19 was 
analyzed as main exposure in a different model and adjusted for cod liver oil use 
during the same period to test the vitamin D hypothesis using other dietary sources. 
Finally, we also tested for effect modification by sex and age at disease onset for the 
association between cod liver oil use during adolescence compared to no use and MS 
risk by including an interaction term into an age-and-sex-adjusted model.  
 
3.2. Articles 2 and 3- The Norwegian Conscript Service Database studies 
3.2.1 Data source, study design, and ethical approval 
We conducted two population-based nested case-control studies within the historical 
cohort of almost all Norwegian men (about 90% of the entire male population) born 
in 1950 to 1995 who participated in the compulsory Norwegian conscription 
examination at age 18 or 19 (n=1,308,872) to be evaluated for military service. 
Information collected during this examination is registered in the Conscript Service 
Database and was made available to us by the Norwegian Armed Forces through the 
governmental agency Statistics Norway. The database was linked to the Norwegian 
MS registry to identify men developing MS later in life. The unique national 
identification number of each Norwegian citizen/resident was used to conduct the 
linkage. As the conscription data is sensitive and classified, we were not allowed to 
use the entire cohort as a control population. In order to maximize power, six male 
 44 
controls were randomly selected from men registered in the Conscript Database, who 
did not go on to develop MS during life, frequency-matched to all the cases in the MS 
registry born in 1950-95 (n=3,526). Since women were, however, granted access to 
the military in more recent years and we only had male controls, we finally included 
only male cases from the MS registry in this study, resulting in an about 1:20-ratio 
and a similar distribution of year of birth between male cases and controls. 
The Regional Ethics Committee for Medical and Health Research in Western Norway 
approved these studies. At inclusion in the MS registry, MS patients gave their 
written informed consent for their data to be used for research. The committee waived 
the need for controls’ consent due to major public interest in the study questions and 
under the condition that Statistics Norway would perform the registry linkage and 
issue anonymized data files for analyses, which we complied with.  
3.2.2 The Norwegian Conscript Service Database 
Norwegian men were conscripted at age 19 if born before 1976 and age 18 if born 
after that. Among non-conscripted men are physically and mentally disabled 
individuals, prison inmates, nationals living abroad or working at sea.323 The 
examination routinely included a physical examination with measurement of height 
and weight, a cognitive performance, and a physical fitness test.  
Cognitive performance was assessed in men born in 1950-95 at conscription by a 
comprehensive validated test timed at in total 53 minutes for 120 questions including 
a 1) mathematical, 2) word synonym, and 3) figure subtest, assessing 1) logical 
reasoning, arithmetic, algebraic abilities, 2) verbal ability, abstract reasoning, 
memory, and 3) logical and abstract reasoning.323, 324 Subtests 1) and 2) resemble the 
arithmetic and vocabulary components of the Wechsler Adult Intelligence Scale 
(WAIS), one of the most commonly used intelligence quotient (IQ)-tests for adults, 
while subtest 3) is similar to Raven’s Progressive Matrices, a non-verbal intelligence 
test. After integrating the standardized scores of the equally weighted subtests, the 
result of the cognitive test was issued as a normally distributed single-digit overall 
score on a nine-point standard scale, (“Stanine”, Standard Nine), i.e. a score from 1 to 
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9 for lowest to highest performance with a mean of 5 and SD of 2. This scale is 
readily used by the military in different countries. The test-retest reliability is high 
(0.84 for the math, 0.90 for the vocabulary, 0.72 for the figure subtest), and the 
overall Stanine score correlates well with the IQ-score as measured by WAIS 
(r=0.75).323, 324 
As part of the physical check, weight and height were recorded in this cohort, with 
which we determined BMI (weight in kg/ height in m2). Further, the majority of men 
born in 1950-75 underwent a physical fitness test at conscription, while a smaller part 
(about 20%) underwent it during the military service and these scores were not 
available to use. The fitness test consisted of a timed 3000 m run assessing maximal 
endurance.325 The test result, also converted to a score on the Stanine scale, correlates 
well with personal 8 km cross-country racing (r=0.79) and 30 km marching (r=0.59) 
times. The fitness score at conscription can therefore be considered a measure of 
aerobic endurance and cardiorespiratory fitness. 
3.2.3 The Norwegian MS registry and biobank 
The MS registry, a valuable tool started in 2001 to promote MS research and 
facilitate patient care, was used to identify MS cases, the year of clinical MS onset, 
and initial disease course.319 At the time of linkage for these studies in 2015, 
approximately 50-60% of all MS patients in Norway were included in the database, 
and all neurologic departments in the country had at least a proportion of their 
patients registered (26-100%). The coverage was estimated through the National 
Patient Registry (NPR) in Norway including International Classification of Diseases 
(ICD)-10 codes of MS registered for patients at hospital admission, treatment at day-
units, and outpatient clinics (100%). Care for patients with a chronic disease like MS 
is almost always provided in one of the bigger medical centers of the country, at least 
at some point during the disease course, and not exclusively in private neurologist 
practices. The NPR could have been used to identify MS cases, however, diagnoses 
are unverified, it does not include information on year of onset and MS course, which 
was crucial information for the conduct of our studies. While coverage of the MS 
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registry has increased to 70% in most recent assessments, efforts are made to 
eliminate the regional registration differences completely by establishing registration 
routine at all neurologic departments in Norway. At inclusion in the registry 
neurologists verify the MS diagnosis according to diagnostic criteria (Poser and 
McDonald).66, 67, 326 Since consent is necessary for inclusion, patients who died before 
2001 are not included in the registry. 
3.2.4 Article 2- Statistical analyses 
From the 3,526 individuals in the MS registry born in 1950-95, only the male cases 
were included in the study (n=1,109), as mentioned above. From the Conscript 
Service Database we randomly selected six-times as many controls frequency-
matched on year of birth to all the cases (including female cases) (n=21,156).  
We used the overall Stanine score on the cognitive conscription test as a measure of 
cognitive performance. Since it was a timed test we especially captured information 
on processing speed, the cognitive area most commonly affected in MS-typical 
cognitive impairment.75, 76 To adjust for trends across decades we standardized the 
score of each individual according to mean and SD of overall performance within 5-
year birth cohorts between 1950 and 1995. The standardized scores were then 
centered on a mean of 5 and a SD of 2.  
Analyses were performed in STATA. We investigated whether there were potential 
differences due to low or lower than expected cognitive performance among men 
who went on to develop MS later in life compared to peers from the male Norwegian 
population, potentially indicating MS activity prior to clinical onset. Firstly, we 
calculated the difference (∆) in mean standardized cognitive scores between future 
cases and controls using unpaired two-sided Student’s t-test at a significance level of 
0.05. We compared the performance among cases 1) overall, 2) in subgroups 
according to initial disease course, RR- and PPMS, and 3) stratified further according 
to time from conscription to clinical onset, each to the performance among the control 
group as a whole. For 3) we used 2-year strata from 1-2 to 33-34 and ≥35 years for 
cases overall and those developing RRMS, and 10-year groups, 1-10, 11-20, 21-30, 
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>30 years for those developing PPMS (to account for lower prevalence and later age 
at clinical onset than RRMS). Secondly, using Cox proportional hazards models, we 
assessed the risk of developing MS in the years following conscription among men 
with lowest cognitive score, defined as a result more than 1 SD below the mean 
among the control population, i.e. a score under 3 on the Stanine scale. Low-scoring 
individuals contributed to time at risk from the year of the cognitive test to the year of 
MS onset or 2013, and were compared to the remaining individuals scoring higher 
than that. We performed separate analyses within the strata of years to MS onset and 
did not assume constant hazard ratios across strata. Hazard ratios were interpreted 
and reported as relative risk (RR) together with a 95% CI. In a second step we 
performed a conservative Bonferroni correction for multiple testing within strata of 
time to MS onset. 
3.2.5 Article 3- Statistical analyses 
For this study, we included all the controls (n=19,230) randomly selected frequency-
matched on year of birth to the 3,205 cases in the MS registry born in 1950-75, and 
male cases (n=1,016) born in the same years for the outcome. This period was chosen 
since data on fitness score was not available for those born after 1975. 
We investigated the independent association between the exposures BMI, as measure 
of excess body fat mass, and fitness scores, as proxy of regular vigorous exercise, 
determined in Norwegian men at age 19 during conscription and the risk of MS later 
in life using Cox proportional hazards models. Individuals contributed to time at risk 
from conscription to the year of clinical MS onset or 2013, whichever came first. We 
reported, again, relative risks (RR) and 95% CI at a two-sided significance level of 
0.05. The effect estimates were adjusted categorically for year of birth in 5-year birth 
cohorts between 1950 and 1975. The exposures were assessed both continuously and 
categorically in 1) separate models and 2) then in one model to estimate the 
independent, meaning mutually adjusted, effect on MS risk.  
BMI categories of underweight, normal weight, overweight, and obesity (<18.5, 18.5-
<25, 25-<30, and ≥30 kg/m2) were created according to WHO definitions for the 
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categorical analyses using normal weight men as reference group. Overweight men 
were further subdivided depending on their BMI (25-<27 and 27-<30 kg/m2) and 
compared to normal weight individuals separately. Fitness scores at conscription 
were examined both on the original Stanine scale continuously/categorically and in 
categories of low, medium, and high fitness (score of 1-3, 4-6, and 7-9), using those 
ranked lowest as a reference. 
Sensitivity analyses included, among others, an extension of the analyses of BMI. 
Information on BMI was available for men born in 1975-95 as well, so we examined 
the association to MS risk including later birth cohorts in a simple model adjusted 
only for year of birth. Further, for both exposures we excluded individuals developing 
MS within 10 years from conscription and in a second step, also those developing 
PPMS after conscription with intent to examine whether reverse causality would 




4.1. Article 1 
In the first article, we found a marked inverse significant association between cod 
liver oil use during adolescence and MS risk after adjusting for sex, age, and 
supplementation during the other periods, while neither use during childhood nor 
adulthood were associated with MS in the same model. The results were similar when 
we also adjusted for sun exposure, history of mononucleosis, smoking, body size, 
fatty fish consumption, and education. No significant differences by sex or MS onset 
age were suggested. The results were similar for those who had asked for help to 
complete the questionnaire suggesting again a protective effect of cod liver oil only 
when it had been used during adolescence. The inverse relationship between longer 
continuous supplementation and MS was not incrementally stronger, and use from 
birth to age 30, the longest assessable period, did not suggest the lowest risk.  
During adolescence, higher vitamin D doses in the winter were associated with a 
reduced MS risk suggesting a significant dose-response relationship peaking at 600-
800 IU/day. The findings were similar when we adjusted the model for all covariates 
mentioned above and MS family history. There was no association for adolescent 
intake during the other seasons and MS in the fully adjusted model, additionally 
including supplementation during winter. Higher vitamin D intake from fatty fish in 
adolescence was associated with a significantly reduced MS risk adjusted for all 
covariates. The estimates did not materially change when including supplementation 
during adolescence into the model, but results were no longer significant.  
 
4.2. Article 2 
In the second article, we found that only men with clinical MS onset within two years 
from the conscription examination at age 18 or 19 scored significantly lower on the 
cognitive test compared to the controls, by an equivalent of 6 IQ-points, while there 
was overall no difference in cognitive scores between men who went on to develop 
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MS later in life, regardless of years to MS onset, and those who did not. Accordingly, 
we found an about 2.8-times higher risk of MS, statistically significant also after 
Bonferroni correction, in the two years following conscription among lowest-scoring 
men compared to men who obtained a Stanine score of 3 or higher. However, there 
was no association between scoring lowest and the risk of developing MS beyond 
two years after the cognitive test at conscription. 
In the analyses according to initial MS course, we observed similar results for men 
who went on to develop RRMS after conscription compared to controls with 
significantly lower cognitive scores only among those who developed first symptoms 
within 2 years and a higher MS risk only the first years following conscription among 
men with lowest scores. However, men developing PPMS with first progressive 
symptoms up to 20 years after conscription scored significantly lower at the cognitive 
test, equivalent to a 4.6-6.9 IQ-point difference. The risk of developing PPMS was 2-
3 times higher within the 20 years following conscription among individuals who 
obtained Stanine scores of below 3 compared to those with a score of 3 or higher on 
the cognitive test. The association was no longer significant after applying the 
Bonferroni method to correct conservatively for multiple comparisons. 
 
4.3. Article 3 
In the third article, we found that a BMI ≥25 kg/m2 among 19-year-old men was 
associated with a significantly elevated risk of MS later in life, independent of fitness. 
Overweight individuals had an up to 2 times higher disease risk, while the results 
among obese individuals were difficult to interpret due to low sample size that was, 
however, in line with the sex- and age-specific obesity prevalence in those decades in 
Norway. The associations were more marked among overweight individuals when we 
excluded individuals who might have been in a prodromal MS phase. 
Interestingly, we observed a significant inverse association with significant p for 
trend between fitness and MS risk that was independent of an effect through BMI. 
The physically fittest men at conscription showed a statistically significant 31% 
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lower risk of MS compared to the most unfit ones according to the endurance test at 
conscription at age 19. The protective effect was suggested to be stronger in the 
sensitivity analyses when we excluded men developing MS within 10 years, and 
further, those who went on to develop PPMS.   
 52 
5. Discussion  
5.1. Interpretation and contribution of the findings 
The findings in this thesis suggest that ensuring adequate vitamin D levels to decrease 
MS risk is most relevant during adolescence and there is a dose-response relationship 
indicating the most protective effect at supplemental doses of 600-800 IU/day during 
winter, when sun-induced production is insufficient. Although several previous 
papers suggested that adolescence is the crucial period, the overall findings on timing 
of vitamin D exposure are inconsistent proposing exposure during childhood,271 
adolescence,254, 272 both,255 or adulthood248 to matter most. In utero exposure may, in 
addition, be of importance for MS risk modification.209, 210, 327 However, no previous 
study could compare all the different postnatal ages systematically using one 
methodology and adjust for the mutual effect of vitamin D supplementation in each 
period as was possible here. We were, further, able to adjust for relevant risk factors.  
The design and size of this study allowed testing hypotheses related to vitamin D 
more in detail. As MS is a rare disease, prospective studies usually lack power to 
examine timing aspects in detail and would need to, ideally, assess exposures from 
birth and follow participants for decades for prospective analyses. In fact, even the 
large Nurses’ Health Study cohorts had limited power to detect a significant effect 
using recalled information on exposure to dietary vitamin D during adolescence.272 
To our knowledge, further studies on this topic have, so far, not been published. 
The findings in the first article indicate an effect of supplemental vitamin D intake 
only in the winter and a previous study based on the EnvIMS data in the same region 
observed an inverse association of sun exposure and MS risk only in the summer.253 
Taken together these findings support that the suggested protective effect is likely 
mediated through vitamin D and not through other sunlight-related factors, at least 
not exclusively. Which mechanisms underlie the heightened susceptibility during 
early life exactly, is unknown.  
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These findings contribute with knowledge regarding the stage in life, in which it may 
be crucial to ensure adequate vitamin D levels. Intervention trials would need to 
consider this knowledge for a valid design. It is difficult to make concrete public 
health recommendations based on this study only, but evidence on susceptibility 
periods is converging and overall these findings support ensuring healthy vitamin D 
levels during early life, which might be especially important for individuals at higher 
risk of MS, like those with positive family history.  
In this project, we also found that men who went on to develop MS within 2 years 
from cognitive assessment at age 18-19 performed worse cognitively compared to 
men who did not go on to develop MS. This suggests that MS is active with subtle 
CNS-specific signs beyond MRI-detectable activity years prior to the first specific 
neurologic MS symptom. Prodromal MS might last several years among men 
developing RRMS, and up to decades among men developing PPMS. These findings 
are novel as this is, to our knowledge, the first study that tried to prospectively 
quantify and assess the temporal aspect of prodromal MS. Interestingly, an 
Argentinian case-control study previously reported a correlation between school 
performance among students during the last high school year and time to first MS 
symptoms suggesting prodromal disease activity in those who were about to develop 
MS, but the study was too small to assess the timing in detail.179 A prospective study 
using Swedish military data observed, consistent with our findings, no overall 
cognitive performance difference among future cases and controls, but the authors did 
not examine the temporal relationship to clinical onset.313 Three previous studies 
described the presence of fatigue, depression, and subtle neurologic symptoms 
suggestive of demyelination prior to clinical MS onset, but all were retrospective and 
did not include a comparison group.328-330 Studies on RIS give valuable insights, but 
those conducted were small.161, 167, 169 Moreover, studies including RIS patients are 
not prospective with regard to prodromal MS. After our paper was published, two 
interesting studies on the MS prodrome followed. Using a cohort of relatives of MS 
patients, individuals considered at higher risk of MS, Xia and colleagues found 
significantly more subclinical abnormalities suggestive of MS in asymptomatic 
participants with a higher risk score.331 In a recent prospective study, Wijnands et al. 
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detected significantly more health-care usage up to 5 years prior to first 
demyelinating event, increasing with approaching clinical onset, among MS patients 
compared to matched controls suggestive of a measureable MS prodrome.332 
 
Figure 7: The natural history of multiple sclerosis. 
The chart illustrates schematically the natural history of multiple sclerosis and the 
relationship between symptoms, phenotypes, pathology, and diagnosis. Reprinted by 
permission from Elsevier: The Lancet Neurology 16: 413,333 
http://www.thelancet.com/journals/laneur/issue/current, © Copyright 2017 
These findings contribute with new knowledge about the natural history of MS, 
particularly latent MS and differences according to initial disease course. This field is 
little understood beyond RIS studies, but is starting to get more attention.331, 332 
Interestingly, the prodromal phase might be especially long among individuals 
developing PPMS and parallel the relapsing stage in RRMS patients that starts on 
average earlier in life, further supporting the unifying disease concept. Clinical PPMS 
is characterized by steady disability accumulation and might correspond to SPMS.122 
Knowledge about PPMS, which seems more elusive than RRMS, is needed also to 
understand how to best conduct research on this phenotype. As degenerative 
processes could be present prior to inflammatory activity, we might have to rethink 
the chronology of pathological events, classic onset symptoms, and phenotypes 
throughout the entire disease course (Figure 7). Further, these findings need to be 
considered when designing studies on putative etiologic factors and evaluating the 
likelihood of reverse causality. They might also help in the public discussion of 
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whether certain drugs, e.g. vaccines, might have at all been able to trigger MS 
considering subclinical onset and temporal aspects. Clinically, these results might 
contribute to the evaluation of individuals presenting with RIS. Cognitive testing 
might help to detect those at higher risk of developing CIS or MS within some years 
and requiring closer follow-up. Finally, findings on the MS prodrome open an avenue 
for anticipating MS diagnosis and evaluating whether earliest intervention can 
positively influence long-term outcomes.333 
In the last article of this thesis, we found an independent association between higher 
BMI, an indicator of excess adipose tissue, and lower aerobic fitness, an indicator of 
little cardiorespiratory exercise, and an increased risk of MS. This not only confirms 
previous findings among women293 that large body size during adolescence might be 
a modifiable risk factor for MS also among men, but importantly points to that 
exercise might potentially also be a modifiable protective factor with an effect that 
cannot be explained through a positive impact of exercise on body composition, and 
deserves further investigation beyond its effect on disease progression.305, 306, 308, 310 In 
consideration of our findings in article 2, the sensitivity analyses excluding men, 
whose exercise level might have been affected by prodromal MS, yielded similar 
results and make reverse causality seem a less likely explanation for these findings. 
Previous studies on the role of exercise on MS risk are scarce. A prospective study 
using Swedish military data reported a significantly lower fitness performance among 
recruits who later developed MS compared to controls.313 The findings from the 
Nurses’ Health Studies are more challenging to interpret.312 The significant link with 
self-reported physical activity weakened after excluding women who might have 
been in a prodromal phase, after introducing a 6-year lag, and the authors interpreted 
the association therefore overall as due to reverse causation. However, they reported a 
result for the exposure during late adolescence that was similar to our results, so they 
might not have captured the relevant exposure when assessing women, on average 34 
and 53 years old. These inconsistencies should not be dismissed and deserve further 
investigation. We reported an association among young men who still have the 
possibility to develop MS considering average MS onset age. Recently, Wesnes and 
colleagues examined the role of vigorous physical activity in the context of the 
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EnvIMS study and reported a similar association as we did after adjusting for the 
established MS risk factors like sun exposure and smoking.334 
Linking BMI to MS among men strengthens evidence for a role of this factor in MS 
etiology, as a biological difference by sex seemed little substantiated. However, this 
study also suggests that BMI is not a valid measure of body fat % among young men, 
corroborating prior concerns.335 Further, we contributed with new findings on a 
candidate modifiable factor, exercise, for MS etiology. Overall, the last article took 
the findings of the previous articles into account by examining a potential modifiable 
risk factor for MS in late teens and evaluating the likelihood of reverse causality.  
Mechanisms underlying a potential protective effect of exercise against MS are 
unknown and can only be speculated. Exercise could have immune-regulatory 
effects.336, 337 However, it should be further investigated whether vitamin D levels or 
smoking habits influence fitness in a way to entirely confound the association, 
although so far only a small effect of vitamin D on muscle strength was most 
consistently reported.338-340 The strongest predictor of higher cardiorespiratory fitness 
seems to be regular purposeful vigorous aerobic exercise.341 
In summary, this thesis operated at the margin between susceptibility periods and 
prodromal MS, contributing with knowledge on the timing and distinction of these 
two aspects, which is important in order to understand and investigate MS etiology 
and pathomechanisms. The search for new potential modifiable risk factors ought to 
rigorously take into account these disease-specific aspects.  
 
5.2. Methodological considerations  
5.2.1 Merits and challenges of observational studies 
Epidemiology studies the frequency, distribution, and determinants of health- and 
disease-related states and outcomes on a population or group level.18, 342 Its goal is to 
prevent morbidity and mortality and improve public health. Non-experimental 
epidemiologic research, like the articles in this thesis, is observational, and reports 
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associations estimating the effect when the null hypothesis of no relationship is 
rejected.18, 343 Still, association does not equal causation.180 The best evidence comes 
from double-blinded randomized controlled trials (experimental epidemiology), as 
they allow if well designed and properly conducted, for causal interpretation of the 
findings.18 The random allocation of participants to the exposure of interest or not, 
creates on average two overall comparable groups with regard to individual and 
extraneous factors differing, except by chance, only in the exposure.343 Observational 
studies are more prone to systematic differences among the comparison groups since 
the exposure is not randomly assigned, but they may be a complementary source of 
knowledge, especially when trials are unfeasible or unethical, as the exposure cannot 
be manipulated or would cause harm.18 In this thesis a trial for objectives 1 and 3 
would be difficult, costly, and unethical considering the known benefits of vitamin D 
and aerobic exercise.240, 341 A trial for objective 2 is not feasible.  
Among non-experimental epidemiologic designs, we prefer longitudinal studies with 
long follow-up using prospective or historical cohorts of individuals that were 
disease-free at recording of exposure information, as these provide results that are 
less prone to bias.18 Registry-linkage studies, as in article 2 and 3, use historical 
cohorts, but are prospective if records including exposure information exist 
independently from later disease occurrence,18 as is the case for conscription records 
in Norway. As these studies rely on existing data collected independently from the 
study purpose, they can lack information, e.g. on potential confounders as in article 3. 
They are, however, less costly and knowledge becomes more readily available. 
Scandinavian countries have been at the forefront for these studies as they have been 
collecting information on demographics, exposures, and outcomes in population 
registries, often over decades.18, 344, 345 The unique national identifier remaining the 
same throughout life can be used to identify an individual across registries and link 
information, but privacy issues can arise. Yet, when studying a rare disease like 
MS,346 even population studies can be too small to investigate the disease in detail. 
Case-control studies are then more efficient to conduct.18 Nevertheless, this design is 
inherently prone to bias related to the selection of cases and controls and exposure 
assessment after disease occurred, often relying on recalled information. 
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5.2.2 Causal thinking in observational studies 
Causal inference would be possible in non-experimental epidemiology if we avoided 
all bias, i.e. systematic differences between exposed/unexposed or diseased/non-
diseased.18 Directed acyclic graphs (DAG) are tools in causal inference, a field 
applying causal thinking in randomized experiments to observational studies to 
facilitate reflection on causal networks potentially underlying the hypothesis, on 
study design, and model building.347, 348 As these can help illustrate limitations in this 
thesis, they are introduced in brief here. DAGs denote the relationship between an 
exposure of interest, here denoted as E, an outcome, denoted as D, and associated 
factors, denoted as C, M, F. Arrows indicate the presumed cause-effect direction 
between these, i.e. the chronology of events. However, independent of the arrow 
directions, any path from E to D needs to be evaluated on whether it is an open or 
closed path. Open paths connecting E and D other than the direct arrow between them 
need to be closed to estimate an unbiased isolated relationship (d-separation). When 
we condition on a variable, meaning adjust for it in the model or conduct an analysis 
stratified on this variable, it can open or close a path, depending on the situation. 
Factors conditioned on are denoted with a box, e.g. C. E and D are associated when:  
1) E causes D (causality) 
2) D causes E (reverse causality) 
3) C is a common cause of E and D that we do not condition on (confounding) 
4) M lies on the path between E and D and we do not condition on it (mediation) 
5) F is a common effect of E and D that we condition on (collider stratification bias).  
5.2.3 Threats to the validity of the findings 
5.2.3.1 Information bias 
Exposure and outcome misclassification due to measurement error can lead to 
information bias, typically when they are differential. This means that there is a 
systematic difference in exposure misclassification among cases and controls or in 
outcome misclassification among exposed and unexposed that can have different 
reasons, for example an error was more frequent or larger in one of the comparison 
groups.18 Non-differential misclassification can occur in prospective and retrospective 
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studies, while differential misclassification occurs more often in retrospective studies, 
in which outcomes are known when conducting the study and can influence error (see 
below). It is difficult to predict the bias direction and whether the association would 
over- or underestimate the true effect. Overall, measurement error can affect the 
validity and the reliability in a study. 
It is possible that exposures in article 2 and 3 were misclassified, meaning that 
measures of cognitive performance, aerobic fitness, or height/weight during 
conscription had some error, but it is unlikely that there was a systematic difference 
among men who went on to develop MS and those who did not. Reassuringly, values 
in the comparison group followed a normal distribution with expected mean. Non-
differential error was probably also limited through use of objective exposure 
measures.  
Non-differential exposure misclassification could have arisen in article 1 if cod liver 
oil supplementation was not remembered correctly as it reached far back in time. 
Limiting eligibility to cases with maximal disease duration of 10 years, adapting the 
ages in the questionnaire to the country’s school system, and inviting participants to 
ask the family for help in recalling information were aimed at reducing this problem. 
Non-differential exposure misclassification could also have occurred if cod liver oil 
use was not a good proxy of vitamin D intake, for example because it did not 
efficiently increase the serum levels in all. We would then have underestimated the 
effect of vitamin D. There is, however, currently no evidence to support this. More 
likely, differential exposure misclassification among cases and controls might have 
occurred and led to recall bias, a form of information bias case-control studies are 
prone to. It results from the differential reporting of past exposures among cases and 
controls, as diseased individuals tend to recall exposures differently due to their 
disease compared to controls. In article 1 we estimated the effect of cod liver oil use 
(CLO) at different ages on MS risk (Figure 8) by using self-reported information in 
EnvIMS (CLO*) as a proxy of true use. The degree of measurement error (ME) in 
recalling exposure information depended on the disease status (MS), indicated by the 
arrow from MS to ME, and may have affected CLO*. Apart from the path between 
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CLO* and MS through CLO, there is an open path through ME that might lead to 
biased estimates of the true effect between CLO and MS. However, as we found an 
association only for adolescence consistent with previous studies, but no association 
at other ages, it is unlikely that recall bias fully explains our findings. Differential 
recall among cases and controls would than need to only be present for the exposure 
during adolescence. 
 
We used the Norwegian MS registry and other population registries to define disease 
status. Probability of misclassification depends on data quality in the registries, but it 
is unlikely that misclassification was related to exposure. There is currently no 
sensitive biomarker for MS and the diagnostic process includes some uncertainty. 
However, since neurologists verified the MS diagnoses according to diagnostic 
criteria reviewing the medical records, validity of the diagnoses is as high as it can 
possibly be considering current standards. The other population registries, controls 
were randomly selected from, have a (nearly) complete coverage.  
5.2.3.2 Selection bias 
Selection bias can occur when the comparison groups are a non-random selection of 
the general source populations and have characteristics related to the exposure and 
the outcome of interest.263 Selection bias is more likely to arise in retrospective case-
control studies as study participants are recruited after disease occurrence, which 
might affect the likelihood of participation. Diseased individuals are more likely to 
participate in research, while non-diseased are more likely to participate if they are 
health-conscious. This means that the outcome leads to a selective inclusion, where 
the controls might be less representative of the source population that gave rise to the 
cases in the study and their characteristics might be related to the exposure of interest. 
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When the majority of eligible cases but a small proportion of eligible controls agrees 
to participate, as indicated by the response rates in article 1, cases and controls might 
not be comparable. The invited controls were less likely to join and those 
participating had a higher socioeconomic status, were maybe more health conscious 
and therefore consumed more cod liver oil during life than the general population. 
This could explain the association in this study. The DAG (Figure 9) shows that cod 
liver oil use (CLO) and disease status (MS) would affect participation in the study (S) 
and create an open path between CLO and MS, since by being able to study only 
individuals actually agreeing to participate, we condition on S and create a collider 
bias. 
 
Selection bias is unlikely but not impossible in population-based cohort studies. Loss 
to follow-up could potentially lead to selection bias. During the long latency between 
conscription and MS onset, loss to follow-up could have occurred, for example, due 
to emigration out of the country before the development of MS. A bias could have 
arisen if likelihood of emigrating was related to exposure status and later disease risk, 
i.e. that men with higher fitness who went on to develop MS were more likely to 
emigrate prior to disease onset than those who did not develop MS. In DAG terms 
this would mean that fitness levels (F) affect emigration (E), and emigration, in turn, 
affects who could participate in the study (S) (Figure 10). There would then be an 
open path from F to MS through E and S, since we condition on a common effect of 
exposure F and outcome MS (collider bias). However, it is unlikely that loss to 
follow-up biased the results in articles 2 and 3 in such a way. Similarly, the 
incomplete coverage of the MS registry could have led to bias if only a non-
representative sample of cases in the country was registered and registration was 
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related to exposure probability. This is, however, also unlikely, as registration did not 
depend, for example on individual factors, like higher BMI or lower fitness, nor were 
MS cases from different regions systematically different. Rather was the registration 
routine not yet established everywhere in the country to the same degree, though 
every neurologic department showed some registration activity. 
5.2.3.3 Confounding  
Confounding is a threat in observational studies as we cannot be sure that the 
comparison groups are exchangeable with regard to other characteristics except for 
the exposure we are interested to study, as in an experimental trial.18 Exposure and 
outcome might have a common cause inducing an association between them that 
gives a biased estimate of the true effect. Confounding bias can be removed as long 
as we have information on the common causes and account for them in the analyses. 
Although we adjusted the models in article 1 for established MS risk factors, positive 
family history, and education, we cannot exclude the presence of unmeasured 
confounding. If there was confounding, it would need to act in an age-dependent 
manner to produce an association for cod liver oil use during one but not all age 
periods. There might also be residual confounding by sun exposure as we adjusted for 
the proxy outdoor activity that might imperfectly capture the exposure. The fact that 
we found an association between supplemental vitamin D intake during the winter, 
but not during the summer when sun exposure contributes most to vitamin D levels 
and dietary intake is negligible, is somewhat reassuring that we accurately captured 
the different entities. 
Further, we cannot exclude the possibility that confounding underlies the findings in 
article 2 and 3. It would have been optimal to adjust the models in article 2 for 
education, as it is associated with cognitive performance and potentially also MS risk, 
as suggested in some previous studies,349 but not all. However, if education were a 
confounder, it would need to act dependent on time to MS onset to explain away the 
observed association pattern conditional on time. Alternatively, education could have 
negatively confounded the association between cognitive performance and MS risk 
(regardless of time to clinical MS onset), but it is, again, difficult to explain how 
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negative confounding acts only among those further away from clinical disease. The 
fact that our findings suggest only a time-dependent effect argues against that 
confounding fully explains our results. Yet, in article 3 confounding is more likely to 
affect the observed associations for high BMI and aerobic fitness, and MS risk, as we 
could not adjust for potential common causes, like vitamin D (VitD) and smoking 
(Sm) (Figure 11). While the results on BMI are in line with previous findings 
including from prospective and Mendelian randomization studies, the results on 
exercise need verification, although measuring exercise level in a valid and reliable 
way is challenging. A sensitivity analysis estimating how strongly potential 
confounders need to be associated with exposure and outcome to remove the 
association, can help evaluating this threat. 
 
5.2.3.4 Reverse causality 
In article 2, we intended to examine reverse causality, i.e. whether MS has an effect 
on cognitive performance prior to clinical onset. Since we did not find a difference in 
cognitive scores among later affected and non-affected men overall, but only when 
considering time to first MS symptom, reverse causality seems likely. In terms of a 
DAG, cognitive performance (C-2) was only associated with clinical disease (MS) 
among those developing first symptoms within 2 years from cognitive testing. This 
means that preclinical disease activity (P) may affect cognitive performance (C-2) a 
few years prior to first classic symptoms and results also in a higher risk of clinical 
disease inducing an association between C-2 and MS as a confounder (Figure 12). C-2 
is at the same time a collider between C-4 and P, blocking the path between cognitive 
performance beyond 2 years prior to first symptom and risk of clinical MS through P. 




The target population of this thesis includes individuals and populations at risk of 
MS. While the findings in article 2 and 3 might be generalizable to Western 
populations, limited generalizability may be due to the fact that we were able to only 
study white men and further studies need to verify whether similar findings can be 
confirmed among women and individuals of other ethnicity. Our results extend the 
generalizability of previous studies reporting a more consistent link between high 
BMI and MS risk among women to men.  
As MS is a heterogeneous disease, the MS registry needs to include patients across 
the distribution of disease course and severity to be representative, which seems the 
case even though the coverage was not complete. MS cases with very benign disease 
might have been less represented, as they were maybe less likely to be followed at 
neurologic departments. Benign MS is rare, and the large majority of MS cases 
receive some clinical follow-up, independently of severity. Registered MS patients 
are most likely a random representative sample of all MS cases in Norway and 
findings might be generalizable to other MS patients of similar populations.  
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6. Conclusions and outlook 
We have contributed with knowledge on the timing of environmental risk factors and 
prodromal signs of MS. We investigated the relevant timing of exposure to vitamin D 
to modify MS risk, the nature and timing of prodromal MS according to disease 
course, and finally the independent association between having an excess body fat 
mass and exercising little or at low intensity as a young man, and the risk of MS 
during adulthood.  
Future studies should investigate whether higher doses of vitamin D during childhood 
and adulthood suggest a similar protective effect as observed for the exposure during 
adolescence. Knowledge is needed about which pathophysiological mechanisms 
underlie the particular vulnerability during adolescence. Further investigations on 
prodromal MS are also warranted, especially on the duration of the prodromal phase, 
on pathological correlates characterizing subclinical disease activity, and on triggers 
of clinical disease. In addition, future studies on the effect of exposure to excessive 
adipose tissue in early life on risk of developing MS could consider using other 
measures than BMI among men. Finally, further studies are needed to confirm 
findings linking vigorous exercise to a lower MS risk. 
 66 
References 
1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517. 
2. Simpson S, Jr., Taylor BV, van der Mei I. The role of epidemiology in MS research: 
Past successes, current challenges and future potential. Mult Scler 2015;21:969-977. 
3. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its 
assessment in multiple sclerosis: integrating physical and psychological components of 
wellbeing. Lancet Neurol 2005;4:556-566. 
4. Disanto G, Berlanga AJ, Handel AE, et al. Heterogeneity in multiple sclerosis: 
scratching the surface of a complex disease. Autoimmune Dis 2010;2011:932351. 
5. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple 
sclerosis: the 2013 revisions. Neurology 2014;83:278-286. 
6. van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: pathology 
of the time frame of MS. Neuropathol Appl Neurobiol 2000;26:2-10. 
7. Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Mortality in 
patients with multiple sclerosis. Neurology 2013;81:184-192. 
8. Lunde HMB, Assmus J, Myhr KM, Bo L, Grytten N. Survival and cause of death in 
multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry 
2017;88:621-625. 
9. Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev 
Neurol 2017;13:375-382. 
10. Benedict RH, Wahlig E, Bakshi R, et al. Predicting quality of life in multiple 
sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, 
and behavior change. J Neurol Sci 2005;231:29-34. 
11. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive 
dysfunction in multiple sclerosis. II. Impact on employment and social functioning. 
Neurology 1991;41:692-696. 
12. Comi G, Radaelli M, Soelberg Sorensen P. Evolving concepts in the treatment of 
relapsing multiple sclerosis. Lancet 2017;389:1347-1356. 
13. Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: 
prospects for disease therapy, repair, and restoration of function. Lancet 2017;389:1357-
1366. 
14. Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis - 
a review of approved medications. Eur J Neurol 2016;23 Suppl 1:18-27. 
15. Browne P, Chandraratna D, Angood C, et al. Atlas of Multiple Sclerosis 2013: A 
growing global problem with widespread inequity. Neurology 2014;83:1022-1024. 
16. MS International Federation: Atlas of MS 2013, Mapping Multiple Sclerosis around 
the world. [online]. Available at: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-
MS.pdf. Accessed 02/08/2017. 
17. Kurtzke JF. Epidemiologic contributions to multiple sclerosis: an overview. 
Neurology 1980;30:61-79. 
18. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd Edition. 
Philadelphia, PA: Lippincott Williams & Wilkins, 2008. 
19. Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of 
multiple sclerosis? J Neurol Sci 2014;344:171-181. 
20. Evans C, Beland SG, Kulaga S, et al. Incidence and prevalence of multiple sclerosis 
in the Americas: a systematic review. Neuroepidemiology 2013;40:195-210. 
 67 
21. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple 
Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-
Analysis. Neuroepidemiology 2015;44:232-244. 
22. Cristiano E, Rojas J, Romano M, et al. The epidemiology of multiple sclerosis in 
Latin America and the Caribbean: a systematic review. Mult Scler 2013;19:844-854. 
23. Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple 
Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review. 
Neuroepidemiology 2016;46:209-221. 
24. Kingwell E, Marriott JJ, Jette N, et al. Incidence and prevalence of multiple sclerosis 
in Europe: a systematic review. BMC Neurol 2013;13:128. 
25. Toro J, Cardenas S, Fernando Martinez C, Urrutia J, Diaz C. Multiple sclerosis in 
Colombia and other Latin American Countries. Mult Scler Relat Disord 2013;2:80-89. 
26. Kurtzke JF. General features on the prevalence of multiple sclerosis. J Indian Med 
Prof 1964;11:4896-4901. 
27. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in US 
veterans: III. Migration and the risk of MS. Neurology 1985;35:672-678. 
28. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a 
systematic review. Neurology 2008;71:129-135. 
29. Kurtzke JF, Beebe GW, Norman JE, Jr. Epidemiology of multiple sclerosis in U.S. 
veterans: 1. Race, sex, and geographic distribution. Neurology 1979;29:1228-1235. 
30. Wallin MT, Culpepper WJ, Coffman P, et al. The Gulf War era multiple sclerosis 
cohort: age and incidence rates by race, sex and service. Brain 2012;135:1778-1785. 
31. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam 
era and later military service: race, sex, and geography. Ann Neurol 2004;55:65-71. 
32. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 
2013;13:3-9. 
33. Alonso A, Jick SS, Olek MJ, Hernan MA. Incidence of multiple sclerosis in the 
United Kingdom : findings from a population-based cohort. J Neurol 2007;254:1736-1741. 
34. Koch-Henriksen N, Bronnum-Hansen H, Hyllested K. Incidence of multiple sclerosis 
in Denmark 1948-1982: a descriptive nationwide study. Neuroepidemiology 1992;11:1-10. 
35. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple 
sclerosis epidemiology. Lancet Neurol 2010;9:520-532. 
36. Ramagopalan SV, Giovannoni G, Yeates DG, Seagroatt V, Goldacre MJ. Sex ratio of 
infectious mononucleosis and possible relevance to multiple sclerosis. Mult Scler 
2013;19:359-361. 
37. Sundstrom P, Nystrom L, Hallmans G. Smoke exposure increases the risk for 
multiple sclerosis. Eur J Neurol 2008;15:579-583. 
38. Trojano M, Lucchese G, Graziano G, et al. Geographical variations in sex ratio trends 
over time in multiple sclerosis. PLoS One 2012;7:e48078. 
39. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a 
longitudinal study. Lancet Neurol 2006;5:932-936. 
40. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and 
outcome of multiple sclerosis. Mult Scler 2014;20:520-526. 
41. Palacios N, Alonso A, Bronnum-Hansen H, Ascherio A. Smoking and increased risk 
of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence. Ann Epidemiol 
2011;21:536-542. 
42. Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV. 
Smoking and multiple sclerosis: an updated meta-analysis. PLoS One 2011;6:e16149. 
43. Grytten N, Torkildsen O, Myhr KM. Time trends in the incidence and prevalence of 
multiple sclerosis in Norway during eight decades. Acta Neurol Scand 2015;132:29-36. 
 68 
44. Swank RL, Lerstad O, Strom A, Backer J. Multiple sclerosis in rural Norway its 
geographic and occupational incidence in relation to nutrition. N Engl J Med 1952;246:722-
728. 
45. Berg-Hansen P, Moen SM, Harbo HF, Celius EG. High prevalence and no latitude 
gradient of multiple sclerosis in Norway. Mult Scler 2014;20:1780-1782. 
46. Grytten N, Aarseth JH, Lunde HM, Myhr KM. A 60-year follow-up of the incidence 
and prevalence of multiple sclerosis in Hordaland County, Western Norway. J Neurol 
Neurosurg Psychiatry 2016;87:100-105. 
47. Kampman MT, Aarseth JH, Grytten N, et al. Sex ratio of multiple sclerosis in 
persons born from 1930 to 1979 and its relation to latitude in Norway. J Neurol 
2013;260:1481-1488. 
48. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple 
sclerosis. Nat Rev Neurol 2012;8:602-612. 
49. Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM, Italian Society of 
Paediatric Neurology Study Group on Childhood Multiple S. Multiple sclerosis in children 
under 10 years of age. Neurol Sci 2004;25 Suppl 4:S326-335. 
50. Ruggieri M, Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 
6 years of age. Neurology 1999;53:478-484. 
51. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of 
irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770-782. 
52. Confavreux C, Compston A. The natural history of multiple sclerosis.  McAlpine's 
Multiple Sclerosis, 4th ed. London: Churchill Livingstone Elsevier, 2006. 
53. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis 
assessed by the computerized data processing of 349 patients. Brain 1980;103:281-300. 
54. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 
2007;256 Suppl 1:S5-13. 
55. Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive 
multiple sclerosis. Mult Scler 2002;8:93-97. 
56. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a 
geographically based study. I. Clinical course and disability. Brain 1989;112 ( Pt 1):133-146. 
57. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with 
clinically isolated syndromes, relapsing-remitting and secondary progressive multiple 
sclerosis. Mult Scler 2003;9:260-274. 
58. Koch M, Kingwell E, Rieckmann P, Tremlett H, Neurologists UMC. The natural 
history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 
2010;81:1039-1043. 
59. Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: 
demographic and clinical variables important for the ability to walk and awarding of 
disability pension. Mult Scler 2001;7:59-65. 
60. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive 
multiple sclerosis. Mult Scler 2008;14:314-324. 
61. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the 
secondary progressive phase of multiple sclerosis. J Neurol Sci 2003;206:135-137. 
62. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev 
Immunol 2015;15:545-558. 
63. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and 
pathogenesis. Nat Rev Neurol 2012;8:647-656. 
64. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary 
progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835. 
 69 
65. Ramagopalan SV, Byrnes JK, Orton SM, et al. Sex ratio of multiple sclerosis and 
clinical phenotype. Eur J Neurol 2010;17:634-637. 
66. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple 
sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231. 
67. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 
2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302. 
68. Schumacher GA, Beebe G, Kibler RF, et al. Problems of Experimental Trials of 
Therapy in Multiple Sclerosis: Report by the Panel on the Evaluation of Experimental Trials 
of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965;122:552-568. 
69. Filippi M, Rocca MA, Ciccarelli O, et al. MRI criteria for the diagnosis of multiple 
sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15:292-303. 
70. Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria 
to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 
2002;52:47-53. 
71. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first 
presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120 ( 
Pt 11):2059-2069. 
72. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded 
disability status scale (EDSS). Neurology 1983;33:1444-1452. 
73. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet 
Neurol 2008;7:1139-1151. 
74. Sacca F, Costabile T, Carotenuto A, et al. The EDSS integration with the Brief 
International Cognitive Assessment for Multiple Sclerosis and orientation tests. Mult Scler 
2017;23:1289-1296. 
75. DeLuca J, Johnson SK, Natelson BH. Information processing efficiency in chronic 
fatigue syndrome and multiple sclerosis. Arch Neurol 1993;50:301-304. 
76. DeLuca J, Chelune GJ, Tulsky DS, Lengenfelder J, Chiaravalloti ND. Is speed of 
processing or working memory the primary information processing deficit in multiple 
sclerosis? J Clin Exp Neuropsychol 2004;26:550-562. 
77. Vollmer T, Signorovitch J, Huynh L, et al. The natural history of brain volume loss 
among patients with multiple sclerosis: a systematic literature review and meta-analysis. J 
Neurol Sci 2015;357:8-18. 
78. Jacobsen C, Hagemeier J, Myhr KM, et al. Brain atrophy and disability progression 
in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 
2014;85:1109-1115. 
79. Radue EW, Barkhof F, Kappos L, et al. Correlation between brain volume loss and 
clinical and MRI outcomes in multiple sclerosis. Neurology 2015;84:784-793. 
80. Zivadinov R, Jakimovski D, Gandhi S, et al. Clinical relevance of brain atrophy 
assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev 
Neurother 2016;16:777-793. 
81. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in 
multiple sclerosis. Neurology 2010;74 Suppl 3:S3-7. 
82. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence 
of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 
2015;72:152-158. 
83. Damasceno A, Damasceno BP, Cendes F. No evidence of disease activity in multiple 
sclerosis: Implications on cognition and brain atrophy. Mult Scler 2016;22:64-72. 
84. Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC. Clinical prognostic factors in 
multiple sclerosis: a natural history review. Nat Rev Neurol 2009;5:672-682. 
 70 
85. Stellmann JP, Neuhaus A, Lederer C, Daumer M, Heesen C. Validating predictors of 
disease progression in a large cohort of primary-progressive multiple sclerosis based on a 
systematic literature review. PLoS One 2014;9:e92761. 
86. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of 
long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic 
review. Arch Neurol 2006;63:1686-1691. 
87. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y, Neurologists UBC. 
Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 
2009;73:1616-1623. 
88. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple 
sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006;108:327-332. 
89. Frisullo G, Nociti V, Iorio R, et al. Regulatory T cells fail to suppress CD4T+-bet+ T 
cells in relapsing multiple sclerosis patients. Immunology 2009;127:418-428. 
90. Haas J, Hug A, Viehover A, et al. Reduced suppressive effect of CD4+CD25high 
regulatory T cells on the T cell immune response against myelin oligodendrocyte 
glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005;35:3343-3352. 
91. Venken K, Hellings N, Thewissen M, et al. Compromised CD4+ CD25(high) 
regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated 
with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the 
single-cell level. Immunology 2008;123:79-89. 
92. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-
brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-
1175. 
93. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous 
system-infiltrating T cells and glial cells is associated with active disease in multiple 
sclerosis. Am J Pathol 2008;172:146-155. 
94. Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. N 
Engl J Med 1982;306:1529-1533. 
95. Volpe E, Battistini L, Borsellino G. Advances in T Helper 17 Cell Biology: 
Pathogenic Role and Potential Therapy in Multiple Sclerosis. Mediators Inflamm 
2015;2015:475158. 
96. Izikson L, Klein RS, Luster AD, Weiner HL. Targeting monocyte recruitment in 
CNS autoimmune disease. Clin Immunol 2002;103:125-131. 
97. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV. The 
evidence for a role of B cells in multiple sclerosis. Neurology 2012;78:823-832. 
98. Schirmer L, Srivastava R, Hemmer B. To look for a needle in a haystack: the search 
for autoantibodies in multiple sclerosis. Mult Scler 2014;20:271-279. 
99. Fraussen J, Claes N, de Bock L, Somers V. Targets of the humoral autoimmune 
response in multiple sclerosis. Autoimmun Rev 2014;13:1126-1137. 
100. Waxman SG. Conduction in myelinated, unmyelinated, and demyelinated fibers. 
Arch Neurol 1977;34:585-589. 
101. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection 
in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285. 
102. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple 
sclerosis lesions. Brain 1997;120 ( Pt 3):393-399. 
103. Olsen JA, Akirav EM. Remyelination in multiple sclerosis: cellular mechanisms and 
novel therapeutic approaches. J Neurosci Res 2015;93:687-696. 
104. Ffrench-Constant C, Raff MC. Proliferating bipotential glial progenitor cells in adult 
rat optic nerve. Nature 1986;319:499-502. 
 71 
105. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and 
diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-2712. 
106. Ciccarelli O, Werring DJ, Wheeler-Kingshott CA, et al. Investigation of MS normal-
appearing brain using diffusion tensor MRI with clinical correlations. Neurology 
2001;56:926-933. 
107. Harrison DM, Roy S, Oh J, et al. Association of Cortical Lesion Burden on 7-T 
Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis. JAMA 
Neurol 2015;72:1004-1012. 
108. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin 
Neurol 2002;15:239-245. 
109. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS 
remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor 
recruitment and differentiation. J Neurosci 2002;22:2451-2459. 
110. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in 
multiple sclerosis. Lancet Neurol 2009;8:280-291. 
111. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and 
cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 
2001;124:2540-2549. 
112. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple 
sclerosis: a 5-year clinical and MR study. Brain 2003;126:2528-2536. 
113. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the 
early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70. 
114. McDonald WI, Halliday AM. Diagnosis and classification of multiple sclerosis. Br 
Med Bull 1977;33:4-9. 
115. Antel J, Antel S, Caramanos Z, Arnold DL, Kuhlmann T. Primary progressive 
multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta 
Neuropathol 2012;123:627-638. 
116. Chataway J, Mander A, Robertson N, et al. Multiple sclerosis in sibling pairs: an 
analysis of 250 families. J Neurol Neurosurg Psychiatry 2001;71:757-761. 
117. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 
2006;129:595-605. 
118. Killestein J, Den Drijver BF, Van der Graaff WL, Uitdehaag BM, Polman CH, Van 
Lier RA. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: 
different features in primary progressive disease. Mult Scler 2001;7:145-150. 
119. van Boxel-Dezaire AH, Smits M, van Trigt-Hoff SC, et al. Cytokine and IL-12 
receptor mRNA discriminate between different clinical subtypes in multiple sclerosis. J 
Neuroimmunol 2001;120:152-160. 
120. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum 
autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl 
Acad Sci U S A 2008;105:18889-18894. 
121. Duran I, Martinez-Caceres EM, Brieva L, Tintore M, Montalban X. Similar pro- and 
anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis. 
Mult Scler 2001;7:151-156. 
122. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. 
Brain 2006;129:606-616. 
123. Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin 
Neurol 2014;122:343-369. 
124. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural 
history of multiple sclerosis: a geographically based study 9: observations on the progressive 
phase of the disease. Brain 2006;129:584-594. 
 72 
125. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of 
disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438. 
126. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with 
childhood onset. N Engl J Med 2007;356:2603-2613. 
127. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical 
results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB 
Multiple Sclerosis Study Group. Neurology 1993;43:655-661. 
128. Randomised double-blind placebo-controlled study of interferon beta-1a in 
relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by 
Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 
1998;352:1498-1504. 
129. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-
1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, 
randomised, multicentre study. Lancet Neurol 2009;8:889-897. 
130. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for 
relapsing multiple sclerosis. N Engl J Med 2006;354:911-923. 
131. Investigators CT, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a 
in early multiple sclerosis. N Engl J Med 2008;359:1786-1801. 
132. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b 
delays conversion to clinically definite and McDonald MS in patients with clinically isolated 
syndromes. Neurology 2006;67:1242-1249. 
133. Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-
efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmun 
Rev 2017;16:658-665. 
134. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with 
multiple sclerosis who were treated with first generation immunomodulating drugs. Mult 
Scler 2013;19:765-774. 
135. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary 
Progressive Multiple Sclerosis. N Engl J Med 2017;376:209-220. 
136. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in 
MSSG. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: 
Clinical results. Neurology 2001;56:1496-1504. 
137. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon 
beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 
2003;60:44-51. 
138. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying 
agents and brain volume changes in multiple sclerosis. Neurology 2008;71:136-144. 
139. Roy S, Benedict RH, Drake AS, Weinstock-Guttman B. Impact of Pharmacotherapy 
on Cognitive Dysfunction in Patients with Multiple Sclerosis. CNS Drugs 2016;30:209-225. 
140. Filippini G, Del Giovane C, Clerico M, et al. Treatment with disease-modifying 
drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane 
Database Syst Rev 2017;4:CD012200. 
141. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression 
in multiple sclerosis. Brain 2010;133:1900-1913. 
142. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: 
a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-
1929. 
143. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural 
history of multiple sclerosis. Neurology 2010;74:2004-2015. 
 73 
144. Rudge P. The value of natural history studies of multiple sclerosis. Brain 1999;122 ( 
Pt 4):591-592. 
145. Wingerchuk DM, Weinshenker BG. The natural history of multiple sclerosis: 
implications for trial design. Curr Opin Neurol 1999;12:345-349. 
146. University of California SFMSET, Cree BA, Gourraud PA, et al. Long-term 
evolution of multiple sclerosis disability in the treatment era. Ann Neurol 2016;80:499-510. 
147. Wolfson C, Wolfson DB. The latent period of multiple sclerosis: a critical review. 
Epidemiology 1993;4:464-470. 
148. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 
2012;11:157-169. 
149. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year 
follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-817. 
150. Optic Neuritis Study G. Multiple sclerosis risk after optic neuritis: final optic neuritis 
treatment trial follow-up. Arch Neurol 2008;65:727-732. 
151. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on 
conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582. 
152. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion 
to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe 
study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-1511. 
153. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy 
initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N 
Engl J Med 2000;343:898-904. 
154. Runia TF, Jafari N, Siepman DA, Hintzen RQ. Fatigue at time of CIS is an 
independent predictor of a subsequent diagnosis of multiple sclerosis. J Neurol Neurosurg 
Psychiatry 2015;86:543-546. 
155. Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol 
Neurosurg Psychiatry 2003;74:443-446. 
156. Feuillet L, Reuter F, Audoin B, et al. Early cognitive impairment in patients with 
clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007;13:124-127. 
157. Zipoli V, Goretti B, Hakiki B, et al. Cognitive impairment predicts conversion to 
multiple sclerosis in clinically isolated syndromes. Mult Scler 2010;16:62-67. 
158. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is 
associated with progressive grey matter atrophy in patients presenting with clinically isolated 
syndromes. Brain 2004;127:1101-1107. 
159. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. 
Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol 
Neurosurg Psychiatry 2008;79:1236-1244. 
160. Labiano-Fontcuberta A, Benito-Leon J. Radiologically isolated syndrome: An update 
on a rare entity. Mult Scler 2016;22:1514-1521. 
161. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of 
multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800-805. 
162. Mackay RP, Hirano A. Forms of benign multiple sclerosis. Report of two "clinically 
silent" cases discovered at autopsy. Arch Neurol 1967;17:588-600. 
163. Granberg T, Martola J, Kristoffersen-Wiberg M, Aspelin P, Fredrikson S. 
Radiologically isolated syndrome--incidental magnetic resonance imaging findings 
suggestive of multiple sclerosis, a systematic review. Mult Scler 2013;19:271-280. 
164. Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict 
disease progression in radiologically isolated syndrome. Neurology 2011;76:686-692. 
165. Kantarci OH, Lebrun C, Siva A, et al. Primary Progressive Multiple Sclerosis 
Evolving From Radiologically Isolated Syndrome. Ann Neurol 2016;79:288-294. 
 74 
166. Tornatore C, Phillips JT, Khan O, Miller AE, Hughes M. Consensus opinion of US 
neurologists on practice patterns in RIS, CIS, and RRMS: Evolution of treatment practices. 
Neurol Clin Pract 2016;6:329-338. 
167. Amato MP, Hakiki B, Goretti B, et al. Association of MRI metrics and cognitive 
impairment in radiologically isolated syndromes. Neurology 2012;78:309-314. 
168. Labiano-Fontcuberta A, Martinez-Gines ML, Aladro Y, et al. A comparison study of 
cognitive deficits in radiologically and clinically isolated syndromes. Mult Scler 
2016;22:250-253. 
169. Lebrun C, Blanc F, Brassat D, Zephir H, de Seze J, Cfsep. Cognitive function in 
radiologically isolated syndrome. Mult Scler 2010;16:919-925. 
170. Labiano-Fontcuberta A, Aladro Y, Martinez-Gines ML, et al. Psychiatric 
disturbances in radiologically isolated syndrome. J Psychiatr Res 2015;68:309-315. 
171. Lebrun C, Cohen M, Clavelou P, Sfsep. Evaluation of quality of life and fatigue in 
radiologically isolated syndrome. Rev Neurol (Paris) 2016;172:392-395. 
172. De Stefano N, Stromillo ML, Rossi F, et al. Improving the characterization of 
radiologically isolated syndrome suggestive of multiple sclerosis. PLoS One 2011;6:e19452. 
173. Rojas JI, Patrucco L, Miguez J, Besada C, Cristiano E. Brain atrophy in 
radiologically isolated syndromes. J Neuroimaging 2015;25:68-71. 
174. McDonnell GV, Cabrera-Gomez J, Calne DB, Li DK, Oger J. Clinical presentation of 
primary progressive multiple sclerosis 10 years after the incidental finding of typical 
magnetic resonance imaging brain lesions: the subclinical stage of primary progressive 
multiple sclerosis may last 10 years. Mult Scler 2003;9:204-209. 
175. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk 
factors and prevention. Lancet Neurol 2016;15:1257-1272. 
176. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive 
emergence of the clinical symptoms. Ann Neurol 2008;64:492-498. 
177. Kurtzke JF. On the Time of Onset in Multiple Sclerosis. Acta Neurol Scand 
1965;41:140-158. 
178. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk 
factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9:727-739. 
179. Sinay V, Perez Akly M, Zanga G, Ciardi C, Racosta JM. School performance as a 
marker of cognitive decline prior to diagnosis of multiple sclerosis. Mult Scler 2015;21:945-
952. 
180. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med 
1965;58:295-300. 
181. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet 
Neurol 2010;9:599-612. 
182. Simmons RD, Ponsonby AL, van der Mei IA, Sheridan P. What affects your MS? 
Responses to an anonymous, Internet-based epidemiological survey. Mult Scler 
2004;10:202-211. 
183. O'Gorman C, Lin R, Stankovich J, Broadley SA. Modelling genetic susceptibility to 
multiple sclerosis with family data. Neuroepidemiology 2013;40:1-12. 
184. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 
2004;3:104-110. 
185. Sadovnick AD, Baird PA, Ward RH. Multiple sclerosis: updated risks for relatives. 
Am J Med Genet 1988;29:533-541. 
186. Mumford CJ, Wood NW, Kellar-Wood H, Thorpe JW, Miller DH, Compston DA. 
The British Isles survey of multiple sclerosis in twins. Neurology 1994;44:11-15. 
 75 
187. Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA. Age-
adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 1996;119 ( Pt 
2):449-455. 
188. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC, Canadian Collaborative 
Study G. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl 
Acad Sci U S A 2003;100:12877-12882. 
189. Fogdell A, Hillert J, Sachs C, Olerup O. The multiple sclerosis- and narcolepsy-
associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens 
1995;46:333-336. 
190. Marrosu MG, Murru MR, Costa G, et al. Multiple sclerosis in Sardinia is associated 
and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am J Hum Genet 
1997;61:454-457. 
191. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus 
and risk for multiple sclerosis. Hum Mol Genet 2006;15:2813-2824. 
192. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis 
susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004;74:160-
167. 
193. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple 
sclerosis: an up-to-date review. Immunol Rev 2012;248:87-103. 
194. International Multiple Sclerosis Genetics C, Beecham AH, Patsopoulos NA, et al. 
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple 
sclerosis. Nat Genet 2013;45:1353-1360. 
195. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 
2014;13:700-709. 
196. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and 
their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010;6:156-166. 
197. Ebers G. Interactions of environment and genes in multiple sclerosis. J Neurol Sci 
2013;334:161-163. 
198. Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and 
environmental risk factors for multiple sclerosis. Nat Rev Neurol 2017;13:25-36. 
199. Huynh JL, Casaccia P. Epigenetic mechanisms in multiple sclerosis: implications for 
pathogenesis and treatment. Lancet Neurol 2013;12:195-206. 
200. Ascherio A, Munger KL. Epidemiology of Multiple Sclerosis: From Risk Factors to 
Prevention-An Update. Semin Neurol 2016;36:103-114. 
201. McKay KA, Kwan V, Duggan T, Tremlett H. Risk factors associated with the onset 
of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. 
Biomed Res Int 2015;2015:817238. 
202. van der Mei I, Lucas RM, Taylor BV, et al. Population attributable fractions and joint 
effects of key risk factors for multiple sclerosis. Mult Scler 2016;22:461-469. 
203. Hedstrom AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor 
for multiple sclerosis. Mult Scler 2016;22:1021-1026. 
204. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Progress in neurobiology 
1995;47:425-448. 
205. Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age at 
immigration to Israel. Arch Neurol 1966;15:234-237. 
206. Dean G, Kurtzke JF. On the risk of multiple sclerosis according to age at immigration 
to South Africa. British medical journal 1971;3:725-729. 
207. Detels R, Visscher BR, Haile RW, Malmgren RM, Dudley JP, Coulson AH. Multiple 
sclerosis and age at migration. Am J Epidemiol 1978;108:386-393. 
 76 
208. Hammond SR, McLeod JG, Millingen KS, et al. The epidemiology of multiple 
sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988;111 ( Pt 1):1-
25. 
209. Mirzaei F, Michels KB, Munger K, et al. Gestational vitamin D and the risk of 
multiple sclerosis in offspring. Ann Neurol 2011;70:30-40. 
210. Munger KL, Aivo J, Hongell K, Soilu-Hanninen M, Surcel HM, Ascherio A. Vitamin 
D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the 
Finnish Maternity Cohort. JAMA Neurol 2016;73:515-519. 
211. Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in 
pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. 
BMJ 2010;340:c1640. 
212. Kurtzke JF, Bui Quoc H. Multiple sclerosis in a migrant population: 2. Half-orientals 
immigrating in childhood. Ann Neurol 1980;8:256-260. 
213. Pugliatti M, Riise T, Sotgiu MA, et al. Evidence of early childhood as the 
susceptibility period in multiple sclerosis: space-time cluster analysis in a Sardinian 
population. Am J Epidemiol 2006;164:326-333. 
214. Riise T, Gronning M, Klauber MR, Barrett-Connor E, Nyland H, Albrektsen G. 
Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, 
Norway. Am J Epidemiol 1991;133:932-939. 
215. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the 
role of infection. Ann Neurol 2007;61:288-299. 
216. Poskanzer DC, Schapira K, Miller H. Multiple Sclerosis and Poliomyelitis. Lancet 
1963;2:917-921. 
217. Compston A, Wekerle H, McDonald I. The origins of multiple sclerosis: a synthesis.  
McAlpine's Multiple Sclerosis, 4th ed. London: Churchill Livingstone Elsevier, 2006. 
218. Bach JF. The effect of infections on susceptibility to autoimmune and allergic 
diseases. N Engl J Med 2002;347:911-920. 
219. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin 
Microbiol Rev 1993;6:382-427. 
220. zur Hausen H. Risk factors: What do breast and CRC cancers and MS have in 
common? Nat Rev Clin Oncol 2015;12:569-570. 
221. Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet 1981;2:1290. 
222. Balfour HH, Jr., Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-
specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the 
United States and factors affecting its acquisition. J Infect Dis 2013;208:1286-1293. 
223. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of 
multiple sclerosis: a prospective study. JAMA 2001;286:3083-3088. 
224. Sundstrom P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr 
virus in multiple sclerosis: a prospective study. Neurology 2004;62:2277-2282. 
225. Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A. Anti-Epstein-Barr virus 
antibodies as serological markers of multiple sclerosis: a prospective study among United 
States military personnel. Mult Scler 2011;17:1185-1193. 
226. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. 
Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study 
with long-term follow-up. Arch Neurol 2006;63:839-844. 
227. Levin LI, Munger KL, Rubertone MV, et al. Temporal relationship between elevation 
of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple 
sclerosis. JAMA 2005;293:2496-2500. 
228. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple 
sclerosis: a meta-analysis. Ann Neurol 2006;59:499-503. 
 77 
229. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with the 
Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010;67:824-830. 
230. Hilton DA, Love S, Fletcher A, Pringle JH. Absence of Epstein-Barr virus RNA in 
multiple sclerosis as assessed by in situ hybridisation. J Neurol Neurosurg Psychiatry 
1994;57:975-976. 
231. Peferoen LA, Lamers F, Lodder LN, et al. Epstein Barr virus is not a characteristic 
feature in the central nervous system in established multiple sclerosis. Brain 2010;133:e137. 
232. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus 
infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-2912. 
233. Torkildsen O, Stansberg C, Angelskar SM, et al. Upregulation of immunoglobulin-
related genes in cortical sections from multiple sclerosis patients. Brain Pathol 2010;20:720-
729. 
234. Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus infection is not a 
characteristic feature of multiple sclerosis brain. Brain 2009;132:3318-3328. 
235. Friedman JE, Zabriskie JB, Plank C, et al. A randomized clinical trial of valacyclovir 
in multiple sclerosis. Mult Scler 2005;11:286-295. 
236. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-
remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 
1996;243:214-224. 
237. Holmoy T, Vartdal F. Cerebrospinal fluid T cells from multiple sclerosis patients 
recognize autologous Epstein-Barr virus-transformed B cells. J Neurovirol 2004;10:52-56. 
238. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR 
cross-reactivity in multiple sclerosis. Nat Immunol 2002;3:940-943. 
239. Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-
1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 
2000;173:32-39. 
240. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281. 
241. Engelsen O, Brustad M, Aksnes L, Lund E. Daily duration of vitamin D synthesis in 
human skin with relation to latitude, total ozone, altitude, ground cover, aerosols and cloud 
thickness. Photochemistry and photobiology 2005;81:1287-1290. 
242. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in 
US adults. Nutr Res 2011;31:48-54. 
243. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health 
problem? J Steroid Biochem Mol Biol 2014;144 Pt A:138-145. 
244. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D 
endocrine system essential for good health. Am J Clin Nutr 2008;88:491S-499S. 
245. Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental 
determinants of prevalence (a viewpoint). Part 1: sunlight, dietary factors and epidemiology. 
Intern J Environ Stud 1974;6:19-27. 
246. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the 
distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta 
Psychiatr Scand Suppl 1960;35:132-147. 
247. Leibowitz U, Sharon D, Alter M. Geographical considerations in multiple sclerosis. 
Brain 1967;90:871-886. 
248. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple 
sclerosis. Neurology 2004;62:60-65. 
249. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-
hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838. 
250. Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Vitamin D 
as a protective factor in multiple sclerosis. Neurology 2012;79:2140-2145. 
 78 
251. Munger KL, Hongell K, Aivo J, Soilu-Hanninen M, Surcel HM, Ascherio A. 25-
Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity 
Cohort. Neurology 2017. 
252. Baarnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased 
occurrence of multiple sclerosis. Mult Scler 2014;20:726-732. 
253. Bjornevik K, Riise T, Casetta I, et al. Sun exposure and multiple sclerosis risk in 
Norway and Italy: The EnvIMS study. Mult Scler 2014;20:1042-1049. 
254. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood 
and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007;254:471-477. 
255. van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, 
and risk of multiple sclerosis: case-control study. BMJ 2003;327:316. 
256. Baarnhielm M, Hedstrom AK, Kockum I, et al. Sunlight is associated with decreased 
multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur J Neurol 
2012;19:955-962. 
257. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent 
risk factors for CNS demyelination. Neurology 2011;76:540-548. 
258. Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and Risk of Multiple Sclerosis: A 
Mendelian Randomization Study. PLoS Med 2015;12:e1001866. 
259. Rhead B, Baarnhielm M, Gianfrancesco M, et al. Mendelian randomization shows a 
causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet 2016;2:e97. 
260. Sundstrom P, Salzer J. Vitamin D and multiple sclerosis-from epidemiology to 
prevention. Acta Neurol Scand 2015;132:56-61. 
261. Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J. A systematic 
review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy 
of vitamin D in multiple sclerosis. Neuroepidemiology 2013;40:147-153. 
262. James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV. The effect 
of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler 
2013;19:1571-1579. 
263. Munger KL, Kochert K, Simon KC, et al. Molecular mechanism underlying the 
impact of vitamin D on disease activity of MS. Ann Clin Transl Neurol 2014;1:605-617. 
264. Salzer J, Bistrom M, Sundstrom P. Vitamin D and multiple sclerosis: where do we go 
from here? Expert Rev Neurother 2014;14:9-18. 
265. Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1alpha,25-
dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. 
Arch Biochem Biophys 2002;408:200-204. 
266. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1,25-
dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J 
Immunol 2006;177:6030-6037. 
267. Nashold FE, Hoag KA, Goverman J, Hayes CE. Rag-1-dependent cells are necessary 
for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. 
J Neuroimmunol 2001;119:16-29. 
268. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks 
the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl 
Acad Sci U S A 1996;93:7861-7864. 
269. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of 
murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-1107. 
270. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune 
encephalomyelitis only in female mice. J Immunol 2005;175:4119-4126. 
271. Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences 
risk of multiple sclerosis in monozygotic twins. Neurology 2007;69:381-388. 
 79 
272. Munger KL, Chitnis T, Frazier AL, Giovannucci E, Spiegelman D, Ascherio A. 
Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol 
2011;258:479-485. 
273. Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple 
sclerosis. Am J Epidemiol 2001;154:69-74. 
274. Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in 
multiple sclerosis incidence. Contraception 1993;47:161-168. 
275. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of 
multiple sclerosis. Br J Obstet Gynaecol 1998;105:1296-1299. 
276. Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the 
association between socio-demographic, lifestyle and medical history factors and multiple 
sclerosis. Can J Public Health 2001;92:281-285. 
277. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not 
Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009;73:696-701. 
278. Ramagopalan SV, Lee JD, Yee IM, et al. Association of smoking with risk of 
multiple sclerosis: a population-based study. J Neurol 2013;260:1778-1781. 
279. Briggs FB, Acuna B, Shen L, et al. Smoking and risk of multiple sclerosis: evidence 
of modification by NAT1 variants. Epidemiology 2014;25:605-614. 
280. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. 
Neurology 2003;61:1122-1124. 
281. Salzer J, Hallmans G, Nystrom M, Stenlund H, Wadell G, Sundstrom P. Smoking as 
a risk factor for multiple sclerosis. Mult Scler 2013;19:1022-1027. 
282. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: 
Noninfectious factors. Ann Neurol 2007;61:504-513. 
283. Salzer J, Sundstrom P. Timing of cigarette smoking as a risk factor for multiple 
sclerosis. Ther Adv Neurol Disord 2013;6:205. 
284. Zhang P, Wang R, Li Z, et al. The risk of smoking on multiple sclerosis: a meta-
analysis based on 20,626 cases from case-control and cohort studies. PeerJ 2016;4:e1797. 
285. Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can 
we learn from epidemiology? Lupus 2006;15:737-745. 
286. Hedstrom AK, Hillert J, Olsson T, Alfredsson L. Nicotine might have a protective 
effect in the etiology of multiple sclerosis. Mult Scler 2013;19:1009-1013. 
287. Gao Z, Nissen JC, Ji K, Tsirka SE. The experimental autoimmune encephalomyelitis 
disease course is modulated by nicotine and other cigarette smoke components. PLoS One 
2014;9:e107979. 
288. Odoardi F, Sie C, Streyl K, et al. T cells become licensed in the lung to enter the 
central nervous system. Nature 2012;488:675-679. 
289. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status 
and calcium metabolism. Eur J Clin Nutr 1999;53:920-926. 
290. Simon KC, van der Mei IA, Munger KL, et al. Combined effects of smoking, anti-
EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 
2010;74:1365-1371. 
291. Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of 
pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013;80:548-552. 
292. Munger KL, Bentzen J, Laursen B, et al. Childhood body mass index and multiple 
sclerosis risk: a long-term cohort study. Mult Scler 2013;19:1323-1329. 
293. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US 
women. Neurology 2009;73:1543-1550. 
 80 
294. Gianfrancesco MA, Acuna B, Shen L, et al. Obesity during childhood and 
adolescence increases susceptibility to multiple sclerosis after accounting for established 
genetic and environmental risk factors. Obes Res Clin Pract 2014;8:e435-447. 
295. Hedstrom AK, Olsson T, Alfredsson L. High body mass index before age 20 is 
associated with increased risk for multiple sclerosis in both men and women. Mult Scler 
2012;18:1334-1336. 
296. Wesnes K, Riise T, Casetta I, et al. Body size and the risk of multiple sclerosis in 
Norway and Italy: the EnvIMS study. Mult Scler 2015;21:388-395. 
297. Mokry LE, Ross S, Timpson NJ, Sawcer S, Davey Smith G, Richards JB. Obesity 
and Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med 2016;13:e1002053. 
298. Ascherio A, Munger KL. Weighing Evidence from Mendelian Randomization-Early-
Life Obesity as a Causal Factor in Multiple Sclerosis? PLoS Med 2016;13:e1002054. 
299. Hedstrom AK, Olsson T, Alfredsson L. Body mass index during adolescence, rather 
than childhood, is critical in determining MS risk. Mult Scler 2016;22:878-883. 
300. Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin 
D deficiency: a systematic review and meta-analysis. Obes Rev 2015;16:341-349. 
301. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of 
vitamin D in obesity. Am J Clin Nutr 2000;72:690-693. 
302. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: 
not a passive bystander. Autoimmun Rev 2014;13:981-1000. 
303. Matarese G, Di Giacomo A, Sanna V, et al. Requirement for leptin in the induction 
and progression of autoimmune encephalomyelitis. J Immunol 2001;166:5909-5916. 
304. Matarese G, Procaccini C, De Rosa V. The intricate interface between immune and 
metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? J Leukoc 
Biol 2008;84:893-899. 
305. Dalgas U, Stenager E. Exercise and disease progression in multiple sclerosis: can 
exercise slow down the progression of multiple sclerosis? Ther Adv Neurol Disord 
2012;5:81-95. 
306. Heine M, van de Port I, Rietberg MB, van Wegen EE, Kwakkel G. Exercise therapy 
for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2015;9:CD009956. 
307. Latimer-Cheung AE, Pilutti LA, Hicks AL, et al. Effects of exercise training on 
fitness, mobility, fatigue, and health-related quality of life among adults with multiple 
sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil 
2013;94:1800-1828 e1803. 
308. Motl RW, Dlugonski D, Pilutti L, Sandroff B, McAuley E. Premorbid physical 
activity predicts disability progression in relapsing-remitting multiple sclerosis. J Neurol Sci 
2012;323:123-127. 
309. Motl RW, Sandroff BM. Benefits of Exercise Training in Multiple Sclerosis. Curr 
Neurol Neurosci Rep 2015;15:62. 
310. Prakash RS, Snook EM, Motl RW, Kramer AF. Aerobic fitness is associated with 
gray matter volume and white matter integrity in multiple sclerosis. Brain Res 
2010;1341:41-51. 
311. Bernardes D, Brambilla R, Bracchi-Ricard V, et al. Prior regular exercise improves 
clinical outcome and reduces demyelination and axonal injury in experimental autoimmune 
encephalomyelitis. J Neurochem 2016;136 Suppl 1:63-73. 
312. Dorans KS, Massa J, Chitnis T, Ascherio A, Munger KL. Physical activity and the 
incidence of multiple sclerosis. Neurology 2016;87:1770-1776. 
313. Gunnarsson M, Udumyan R, Bahmanyar S, Nilsagard Y, Montgomery S. 
Characteristics in childhood and adolescence associated with future multiple sclerosis risk in 
men: cohort study. Eur J Neurol 2015;22:1131-1137. 
 81 
314. Steene-Johannessen J, Anderssen SA, HP VDP, et al. Are Self-report Measures Able 
to Define Individuals as Physically Active or Inactive? Med Sci Sports Exerc 2016;48:235-
244. 
315. Ainsworth B, Cahalin L, Buman M, Ross R. The current state of physical activity 
assessment tools. Prog Cardiovasc Dis 2015;57:387-395. 
316. Magalhaes S, Pugliatti M, Casetta I, et al. The EnvIMS Study: Design and 
Methodology of an International Case-Control Study of Environmental Risk Factors in 
Multiple Sclerosis. Neuroepidemiology 2015;44:173-181. 
317. Pugliatti M, Casetta I, Drulovic J, et al. A questionnaire for multinational case-
control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q). Acta 
neurologica Scandinavica Supplementum 2012:43-50. 
318. Alexander J, Frøyland L, Hemre G-I, et al. A comprehensive assessment of fish and 
other seafood in the Norwegian diet http://www.vkm.no/dav/d94dff429b.pdf: The 
Norwegian Scientific Committee for Food Safety (VKM), 2006. 
319. Myhr KM, Grytten N, Torkildsen O, Wergeland S, Bo L, Aarseth JH. The Norwegian 
Multiple Sclerosis Registry and Biobank. Acta Neurol Scand 2015;132:24-28. 
320. The Norwegian Tax Administration: The National Registry [online]. Available at: 
http://www.skatteetaten.no/en/person/National-Registry/This-is-the-National-Registry/. 
Accessed 17/07/2017. 
321. Birgisdottir BE, Brantsaeter AL, Kvalem HE, et al. Fish liver and seagull eggs, 
vitamin D-rich foods with a shadow: results from the Norwegian Fish and Game Study. 
Molecular nutrition & food research 2012;56:388-398. 
322. Stunkard AJ, Sorensen T, Schulsinger F. Use of the Danish Adoption Register for the 
study of obesity and thinness. Research publications - Association for Research in Nervous 
and Mental Disease 1983;60:115-120. 
323. Sundet JM, Barlaug DG, Torjussen TM. The end of the Flynn effect? A study of 
secular trends in mean intelligence test scores of Norwegian conscripts during half a century. 
Intelligence 2004;32:349-362. 
324. Eriksen W, Sundet JM, Tambs K. Register data suggest lower intelligence in men 
born the year after flu pandemic. Ann Neurol 2009;66:284-289. 
325. Malmberg J. Physical fitness tests in the Nordic Armed Forces- A description of 
basic tests protocols. Oslo: The Norwegian Defence University College & Norwegian 
School of Sport Sciences/Defence Institute, 2011. 
326. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for 
multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple 
sclerosis. Ann Neurol 2001;50:121-127. 
327. Nielsen NM, Munger KL, Koch-Henriksen N, et al. Neonatal vitamin D status and 
risk of multiple sclerosis: A population-based case-control study. Neurology 2017;88:44-51. 
328. Berger JR, Pocoski J, Preblick R, Boklage S. Fatigue heralding multiple sclerosis. 
Mult Scler 2013;19:1526-1532. 
329. Byatt N, Rothschild AJ, Riskind P, Ionete C, Hunt AT. Relationships between 
multiple sclerosis and depression. J Neuropsychiatry Clin Neurosci 2011;23:198-200. 
330. Gout O, Lebrun-Frenay C, Labauge P, et al. Prior suggestive symptoms in one-third 
of patients consulting for a "first" demyelinating event. J Neurol Neurosurg Psychiatry 
2011;82:323-325. 
331. Xia Z, Steele SU, Bakshi A, et al. Assessment of Early Evidence of Multiple 
Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members. JAMA 
Neurol 2017;74:293-300. 
 82 
332. Wijnands JMA, Kingwell E, Zhu F, et al. Health-care use before a first demyelinating 
event suggestive of a multiple sclerosis prodrome: a matched cohort study. Lancet Neurol 
2017;16:445-451. 
333. Giovannoni G. The neurodegenerative prodrome in multiple sclerosis. Lancet Neurol 
2017;16:413-414. 
334. Wesnes K, Myhr KM, Riise T, et al. Physical activity is associated with a decreased 
multiple sclerosis risk: The EnvIMS study. Mult Scler 2017:1352458517694088. 
335. Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass index 
in diagnosing obesity in the adult general population. Int J Obes (Lond) 2008;32:959-966. 
336. Handzlik MK, Shaw AJ, Dungey M, Bishop NC, Gleeson M. The influence of 
exercise training status on antigen-stimulated IL-10 production in whole blood culture and 
numbers of circulating regulatory T cells. Eur J Appl Physiol 2013;113:1839-1848. 
337. Wang J, Song H, Tang X, et al. Effect of exercise training intensity on murine T-
regulatory cells and vaccination response. Scand J Med Sci Sports 2012;22:643-652. 
338. Conway TL, Cronan TA. Smoking, exercise, and physical fitness. Prev Med 
1992;21:723-734. 
339. Petchey WG, Howden EJ, Johnson DW, Hawley CM, Marwick T, Isbel NM. 
Cardiorespiratory fitness is independently associated with 25-hydroxyvitamin D in chronic 
kidney disease. Clin J Am Soc Nephrol 2011;6:512-518. 
340. Beaudart C, Buckinx F, Rabenda V, et al. The effects of vitamin D on skeletal muscle 
strength, muscle mass, and muscle power: a systematic review and meta-analysis of 
randomized controlled trials. J Clin Endocrinol Metab 2014;99:4336-4345. 
341. Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine 
position stand. Quantity and quality of exercise for developing and maintaining 
cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: 
guidance for prescribing exercise. Med Sci Sports Exerc 2011;43:1334-1359. 
342. U.S. Centers for Disease Control and Prevention: Principles of Epidemiology in 
Public Health Practice, Third Edition [online]. Available at: 
https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson1/section1.html. Accessed 24th July 
2017. 
343. Fisher RA. The Design of Experiments, 8th edition. New York: Hafner Publishing 
Company, 1971. 
344. A. W. The Medical Birth Registry Norway- an international perspective. 2007. 
345. Reigstad MM, Larsen IK, Myklebust TA, et al. The Nordic Health Registries: an 
important part of modern medical research. Hum Reprod 2016;31:216-217. 
346. Greenland S, Thomas DC. On the need for the rare disease assumption in case-
control studies. Am J Epidemiol 1982;116:547-553. 
347. Hernán MA, Robins JM. Causal Inference: Boca Raton: Chapman & Hall/CRC, 
forthcoming, 2017. 
348. Pearl J. Causality : models, reasoning, and inference, 2nd ed. Cambridge ; New York: 
Cambridge University Press, 2009. 
349. Bjornevik K, Riise T, Benjaminsen E, et al. Level of education and multiple sclerosis 












© The Author(s), 2015.  








A low vitamin D level is one of the factors most con-
sistently associated with multiple sclerosis (MS).1 
Yet, it is not well understood at which age an adequate 
exposure might be especially important and an inter-
vention optimally timed to modify MS risk.2
Observational studies investigating the timing of 
exposure reached different conclusions regarding 
the possibly most susceptible postnatal period: 
childhood,3 adolescence,4 childhood and adoles-
cence,5 adulthood.6 Migration and space-time cluster 
studies also pointed to different postnatal suscepti-
bility periods,7–10 though these findings could also 
reflect the effect of other environmental risk 
factors.2 Furthermore, lower vitamin D exposure and 
serum levels during the prenatal phase have been 
associated with increased risk of MS later in life and 
could mark an independent susceptibility period.11–13
Serum vitamin D levels are influenced by sun expo-
sure and diet.1 Cod liver oil is an important dietary 
vitamin D source in high-latitude countries like 
Norway where there is no sun-induced vitamin D pro-
duction during the winter.14 Norwegian Health 
Authorities have recommended 5 ml of cod liver oil 
daily (400 IU of vitamin D) for more than 60 years to 
prevent diseases like rickets, formerly more prevalent 
in areas with little access to vitamin D-rich fatty 
fish.15 A survey from 1997 estimated that about 35% 
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Abstract
Background: Low vitamin D levels have been associated with an increased risk of multiple sclerosis 
(MS), although it remains unknown whether this relationship varies by age.
Objective: The objective of this paper is to investigate the association between vitamin D3 supplementa-
tion through cod liver oil at different postnatal ages and MS risk.
Methods: In the Norwegian component of the multinational case-control study Environmental Factors In 
Multiple Sclerosis (EnvIMS), a total of 953 MS patients with maximum disease duration of 10 years and 
1717 controls reported their cod liver oil use from childhood to adulthood.
Results: Self-reported supplement use at ages 13–18 was associated with a reduced risk of MS (OR 0.67, 
95% CI 0.52–0.86), whereas supplementation during childhood was not found to alter MS risk (OR 1.01, 
95% CI 0.81–1.26), each compared to non-use during the respective period. An inverse association was 
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of the Norwegian population and 50% of those aged 
60–79 were still using the supplement on a daily 
basis.16
As the literature is inconsistent in delimiting a critical 
window in which vitamin D might act, we investigated 
the association between the postnatal timing of cod 
liver oil supplementation, an important oral vitamin D 
source in Norway, and the risk of developing MS.
Methods
The EnvIMS study
The multi-national multicenter case-control study of 
Environmental Factors In Multiple Sclerosis 
(EnvIMS) was launched to investigate environmental 
risk factors for MS and examine possible differences 
between distinct populations. A self-administered 
postal questionnaire (EnvIMS-Q) was designed 
including detailed questions about age-specific past 
exposures such as sun habits, diet, supplement use, 
past medical history, lifestyle, occupational and hor-
monal factors.17 The questionnaire has been assessed 
for acceptability, feasibility and reliability.17 The 
complete study design and methodology has been 
published elsewhere.17
The Norwegian component of the EnvIMS study was 
approved by the Regional Ethical Committee for 
Medical and Health Research for Western Norway (n. 
11, 18.12.2008). All eligible study participants 
received an invitation to participate in the form of an 
information letter explaining the study objectives, rel-
evance and instructions for participation. Completion 
and return of the questionnaire implied participants’ 
informed consent.
Study population
These analyses used the Norwegian EnvIMS data col-
lected in 2008. The cases, diagnosed according to the 
McDonald criteria,18 were recruited from the 
Norwegian MS-registry and Biobank.19 Only patients 
with disease duration shorter than 10 years were eligi-
ble for participation. Of the 1368 invited cases, 953 
(69.7%) returned the questionnaire. The response rate 
was 72% among women as compared to 64.6% in men.
Controls, frequency-matched on age and sex, were 
randomly selected in a 4:1-ratio from the population-
based National Registry in Norway (Folkeregisteret). 
Of the 4728 invited controls, 1717 (36.3%) partici-
pated. The response rate in women was again higher 
than in men (39.4% vs. 29.4%).
Exposure, outcome and covariates
Cod liver oil is an important source of vitamin D in 
the Norwegian population.16 The recommended one 
teaspoon (two capsules) daily of cod liver oil (5 ml) of 
the most commonly used Norwegian brand (Möller’s, 
Axellus AS, Oslo) contains 10 μg (400 IU) of vitamin 
D3, 250 μg of vitamin A, 10 mg of vitamin E and 1.2 
g of the omega-3 fatty acids EPA and DHA. A 
Norwegian survey estimated that the majority of con-
sumers use one tablespoon (15 ml) as a serving size.20
Given the importance of cod liver oil as a source of 
vitamin D in Norway, the use of this supplement was 
explored in several questions in the EnvIMS-Q. 
Participants were asked to report whether they had 
used cod liver oil or capsules “never” or at ages “0–
6,” “7–12,” “13–15,” “16–18,” “19–24” and “25–
30.” The age-scale was adapted to the Norwegian 
school system. Additionally, the frequency of supple-
ment use at ages 13–19 during the winter and the rest 
of the year was explored using two separate variables 
on a six-point scale including “never/seldom,” “1–3 
times/month,” “1 time/week,” “2–3 times/week,” 
“4–6 times/week” and “7+ times/week.” Another 
question classified the usual quantity of cod liver oil 
consumed at each serving during the same period 
into “no use,” “half a teaspoon,” “one teaspoon,” 
“half a tablespoon” and “one tablespoon or more.” 
The special interest of the investigators in this period 
was based on previous findings indicating that ado-
lescence might be especially important for MS risk 
modification.21
Further, data on important covariates were retrieved 
from the questionnaire. The level of sun exposure was 
estimated by summer outdoor activity at ages “0–6,” 
“7–12,” “13–15,” “16–18,” “19–24,” “25–30” and “in 
recent years,” and quantified as “not that often,” “rea-
sonably often,” “quite often” and “virtually all the 
time.” The frequency of consumption of vitamin 
D-rich fatty fish at main meals at ages 13–19 was 
explored on a six-point scale with “never,” “1 time/
month,” “2–3 times/month,” “1 time/week,” “2 times/
week” and “3 and more times/week” for a) “herring,” 
b) “mackerel,” c) “halibut, flounder” and d) “salmon, 
trout,” respectively. From the information elicited 
about infectious mononucleosis, past occurrence of 
the disease was used as covariate (“yes,” “no” or “I 
don’t remember”). Participants also reported their 
body shape at five-year age intervals based on a nine-
point scale derived from body sketches,22 a figure rat-
ing scale, which has been shown to reflect well 
individuals’ body mass index (BMI).23,24 Information 
on the smoking habits (smoking onset never or after 
versus before MS onset) and the participants’ level of 
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education (elementary, middle, high school or univer-
sity) was also included in the analyses.
Finally, participants reported whether they had a fam-
ily history of MS (affected parent, sibling or child) 
and whether they had asked their parents or another 
person for help in recalling information.
Statistical analyses
Statistical analyses were performed using STATA 
13.1 (StataCorp, College Station, TX, USA). The 
associations between exposure and outcome were 
estimated through logistic regression and reported as 
odds ratios (OR) with 95% confidence intervals (CIs). 
All estimates were adjusted for sex and year of birth 
(six-year categories to create balanced subgroups).
According to the distribution of age at disease onset 
in the cases, an index age with corresponding distri-
bution was assigned to controls taking into account 
age at time of study. Participants were considered 
exposed only if the exposure of interest occurred 
before the index postnatal age or age at disease onset. 
Participants exposed only after this period were con-
sidered unexposed.
Based on reported cod liver oil use at different ages, 
three variables were created: 1) cod liver oil use dur-
ing childhood (ages 0–12) regardless of use during 
the other periods compared to no use during child-
hood, 2) cod liver oil use during adolescence (ages 
13–18) regardless of use during the other periods 
compared to no use during adolescence and 3) cod 
liver oil use during adulthood (ages 19–30) regardless 
of use during the other periods compared to no use 
during adulthood. The effect of these variables was 
estimated in i) separate models adjusted for age and 
sex, ii) simultaneously in the same model and finally 
iii) also adjusted for different covariates.
Additionally, MS risk was compared for cod liver oil 
use continuously from birth up to different ages to 
investigate whether the duration of exposure was 
important. Information about frequency and quantity 
of supplement use at ages 13–19 was analyzed both as 
a categorical and a continuous variable using those 
who reported never having taken cod liver oil or cap-
sules during a certain season as reference.
Consumption frequency of fatty fish during adoles-
cence was examined by assigning scores between 0 
and 5 to each participant to account for how frequently 
on the six-point scale “herring,” “mackerel,” “halibut, 
flounder” and “salmon, trout,” respectively, were 
consumed. These scores were added up to an overall 
score ranging from 0 to 20 reflecting the fatty-fish 
consumption. To facilitate analyses of the overall 
score, a quintile-inspired five-point scale from 1 to 5 
was created grouping overall scores of 0, 1–2, 3–4, 
5–6, ⩾7 and analyzed as a continuous variable.
Further, reported sun exposure during the summer at 
ages 0–12, 13–18 and 19–30, history of infectious 
mononucleosis, smoking prior to MS onset, body size 
at age 15, frequency of consumption of oily fish at 
ages 13–19 and years of education were added to the 
model to adjust for possible confounding. In a second 
step interaction terms were created to test for effect 
modification by sex and age at disease onset.
Results
Mean study age and sex distribution were similar in 
both groups (Table 1). Cases were significantly more 
likely than controls to have smoked before MS onset, 
experienced infectious mononucleosis, reported a 
lower educational level, a large body size at age 15 and 
infrequent summer sun exposure during adolescence.
Timing of cod liver oil use
Supplementation habits did not vary with sex, but 
with age at the time of study. Supplementation during 
childhood, adolescence and adulthood was more 
common among participants born before 1962.
Cod liver oil use was reported by 54.4% of cases and 
55.9% of controls during at least one of the age 
ranges of interest between birth and age 30. 
Information on the age-specific supplementation 
was missing for 11.6% of participants. The associa-
tion between the risk of developing MS and cod liver 
oil use varied considerably depending on the timing 
of the supplementation (Table 2). A marked inverse 
association was observed for intake at ages 13–18 
after adjusting for age, sex and supplementation dur-
ing the other periods. Neither cod liver oil use during 
childhood nor adult life was associated with reduced 
disease risk compared to non-use during those 
periods.
The association between cod liver oil supplementa-
tion during adolescence and MS risk was not mean-
ingfully altered after adjusting for sun exposure, 
infectious mononucleosis, smoking, body size, oily 
fish consumption and education. No significant dif-
ferences were seen in the effect between men and 
women and according to age at disease onset (data not 
shown).
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We observed that 404 cases (42.4%) and 368 controls 
(21.4%) asked for help in completing the question-
naire. Of these, 34.1% vs. 42.2% used cod liver oil dur-
ing childhood, 19.8% vs. 30.2% during adolescence 
and 15.2% vs. 19.4% during adulthood, comparing 
cases and controls, respectively. When restricting the 
analysis of the fully adjusted model 3 (Table 2) to those 
asking for help, the pattern of association remained 
similar. The respective OR (95% CI) were 0.99 (0.66–
1.49) for childhood, 0.67 (0.42–1.06) for adolescence 
and 0.99 (0.64–1.54) for adulthood use.
Continuous supplementation from birth up to a cer-
tain age was increasingly more strongly associated 
with a reduced MS risk the longer the supplementa-
tion lasted, except for the longest period from birth to 
age 30 (Figure 1).
Supplementation during adolescence
Supplementation during adolescence was further ana-
lyzed for seasonality, frequency and habitual serving 
size.
The habit of using (liquid) cod liver oil during adoles-
cence was more common during the winter (33.7% 
and 43.6%) than the rest of the year (19.7% and 
23.9%), both in cases and controls. Information was 
missing for 15.9% of participants for intake during 
winter and 29.3% during the rest of the year. The fre-
quency of intake most often reported during adoles-
cence in the winter, if any, was “7+ times a week” 
both for cases (41.8%) and controls (39.3%). The 
serving size most commonly reported was “1 table-
spoon” for cases (58.7%) and controls (64.3%).
Table 3 shows the association between MS risk and 
increasing doses of vitamin D3 as estimated from the 
frequency and quantity of supplementation in the 
winter during adolescence, suggesting a dose-
response relationship (p trend = 0.001) and the strong-
est protective effect for 600–800 IU/d. The estimates 
did not substantially change after adjusting for a 
selection of confounders (Table 3), nor after also add-
ing family history of MS into the model.
The association was significant for supplementation 
only during the winter. For the supplement use in 
Table 1. Selected characteristics of the Norwegian participants in EnvIMSa,b.
Cases (n = 953) Controls (n = 1717)
Age at study, mean (SD) 44.8 (10.5) 46.0 (10.8)
Male, n (%) 286 (30.0) 461 (26.9)
Age at disease onset, mean (SD) 37.6 (10.2)g n.a.
Disease duration, mean (SD) 7.2 (2.7)g n.a.
Smoking before MS onsetc, n (%) 545 (58.9) 853 (50.7)
Infectious mononucleosis, n (%)  
 “Yes” 160 (17.3) 155 (9.3)
 “No” 729 (78.7) 1486 (88.8)
 “I don’t remember” 37 (4.0) 33 (2.0)
Educational level, n (%)  
 High school or lower 538 (57.1) 802 (47.3)
 University career 402 (42.7) 890 (52.5)
Body size at age 15, n (%)d  
 Normal (silhouette 1–4)e 794 (87.0) 1486 (89.5)
 Large (silhouette 5–9)f 119 (13.0) 174 (10.5)
Summer sun exposure, n (%)  
 Lower vs. higher at age 13–15 302 (32.7)/623 (67.4) 456 (27.4)/1210 (72.6)
 Lower vs. higher at age 16–18 487 (52.4)/443 (47.6) 779 (46.8)/885 (53.2)
EnvIMS: Environmental Factors In Multiple Sclerosis; SD: standard deviation; n: count; n.a.: not applicable.
aMissing data for covariates ranging from 0% to 3.6%.
bCases asked significantly more often for help than controls to recall information when filling out the questionnaire (mother: 34.5 vs. 
17.2%, father: 6.9 vs. 2.5%, other person: 8.3% vs. 4.2%).
cOnly 0.9 % in this group smoked less than three years.
dBased on Stunkard’s figure rating scale.
eBody mass index (BMI) ranges from 18.9 to 23.5 kg/m2.
fBMI ranges from 26.1 to 43.3 kg/m2 including overweight and obesity.
gBased on data from the Norwegian MS-registry and Biobank.
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other seasons we found no evidence of an association 
between doses of cod liver oil during adolescence and 
MS (OR 1.03, 95% CI 0.84–1.26, p trend = 0.773, 
adjusted for supplementation during adolescence in 
the winter and the covariates listed in the methods).
Fish consumption
Consumption of fatty fish during adolescence was 
associated with a significant reduction in risk for later 
MS development (OR 0.92, 95% CI 0.86–0.99, p 
trend = 0.047, adjusted for all covariates mentioned in 
Table 2. Association between cod liver oil use at different ages and the risk of MS.
Use compared to no use of cod liver oil during
 Childhood (0–12 y)a Adolescence (13–18 y)a Adulthood (19–30 y)a
Cases n (%) 301 (31.8) 196 (20.6) 165 (17.4)
Controls n (%) 631 (36.9) 473 (27.6) 309 (18.0)
 OR (95% CI)b OR (95% CI)b OR (95% CI)b
Model 1c 0.82 (0.69–0.97)f 0.70 (0.58–0.85)g 1.00 (0.81–1.24)
Model 2d 1.01 (0.81–1.26) 0.67 (0.52–0.86)h 1.17 (0.93–1.47)
Model 3e 1.01 (0.79–1.29) 0.72 (0.55–0.96)f 1.18 (0.92–1.51)
MS: multiple sclerosis; y: years; n: count; OR: odds ratio; CI: confidence interval.
aContinuous or periodical use regardless of prior and subsequent use.
bOR of MS for age at disease onset after the exposure period of interest by cod liver oil use during specific age periods compared to 
no use during the same period.
cModel 1: Separate model for each age period. Adjusted for age and sex.
dModel 2: All three age periods included in the same model. Adjusted for age and sex.
eModel 3: All three age periods included in the same model. Adjusted for age, sex, smoking before disease onset, history of infec-
tious mononucleosis, sun exposure, body shape at age 15, education, and consumption of fatty fish.
fP value < 0.05.
gP value < 0.0001.
hP value < 0.005.
Figure 1. Association between cod liver oil use during increasingly longer age-periods and MS risk.
MS: multiple sclerosis; OR: odds ratio; CI: confidence interval. n: count.
OR of MS in groups with cod liver oil use continuously from birth up to a specific age compared to those who reported no use in the past 
and number of cases and controls.
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the methods). This OR was related to one step on the 
five-point scale and is equivalent to an OR of 0.72 
comparing most frequent with no fish consumption. 
When further adjusting for cod liver oil use during 
adolescence, the result did not meaningfully change, 
but was no longer significant (OR 0.93, 95% CI 0.86–
1.01, p trend = 0.085).
Discussion
We found an inverse association between MS risk and 
cod liver oil supplementation during adolescence and 
a dose-response protective effect suggested for higher 
dosages of vitamin D consumed through cod liver oil. 
However, no association was observed for supplemen-
tation during childhood or adulthood. These findings 
suggest that adolescence might be an especially sus-
ceptible period for disease risk modification through 
dietary vitamin D and are in line with previous obser-
vational4,21 and experimental25 studies. Other environ-
mental risk factors like infectious mononucleosis,26 
high BMI24 and other lifestyle factors27 have also been 
suggested to act mainly during adolescence.
Previous studies in the same area found that sun expo-
sure through outdoor activity during adolescence was 
associated with a decreased disease risk only when 
exposure occurred during the summer,4,28 while the 
association between MS and cod liver oil use during 
adolescence in the present study was only significant 
for intake during the winter when sun-induced vita-
min D-production ceases. These seasonal differences 
suggest that the risk-modifying effect is vitamin D 
mediated.
A low vitamin D level is one of the risk factors most 
consistently associated with an increased risk of MS. 
A prospective study reported a decreased MS risk 
among adult nurses comparing supplemental intake of 
⩾400 IU/d of vitamin D to no intake.6 However, it is 
unclear how vitamin D levels in adulthood correlate 
with those during adolescence.
Our findings indicate an especially sensitive period 
during adolescence for MS risk modification but 
probably not the only one.21 Higher doses of vitamin 
D may be needed during childhood and adulthood to 
reach the same degree of risk modification as during 
adolescence.21,25 Even though we did not find an 
association between overall cod liver oil use during 
childhood or adulthood and MS risk, we could not 
evaluate whether a protective effect was restricted to 
high-dose users at these ages, as this information was 
not collected.
A prospective study in the United States (US) did 
not find an association between total recalled die-
tary vitamin D intake during adolescence and MS 
risk.29 Intake of ⩾400 IU/d of vitamin D from mul-
tivitamins during adolescence showed, however, a 
nonsignificant reduced MS risk of an order of mag-
nitude similar to the findings in our study under the 
rare-disease-assumption.29 Power might not have 
been optimal to yield significant results particularly 
since diet contributes only to a small extent to the 
vitamin D status compared to sun exposure in the 
studied area.29 In the area of the present study there 
is virtually no contribution of sun exposure during 
winter.
Table 3. Association between average daily intake of vitamin D3 through monthly supplemented cod liver oil in the 





Cases n (%) Controls n (%) ORa 95% CI
Noneb – 525 (66.0) 784 (56.1) 1.00 –
1–15 ⩽ 200 79 (9.9) 160 (11.5) 0.74 0.55–0.99c
16–30 201–400 55 (6.9) 125 (9.0) 0.68 0.48–0.95c
31–45 401–600 14 (1.8) 38 (2.7) 0.58 0.31–1.08
46–60 601–800 32 (4.0) 104 (7.4) 0.46 0.31–0.70d
>60 >800 90 (11.3) 186 (13.3) 0.77 0.58–1.02
MS: multiple sclerosis; n: count; ts: teaspoons; IU: international units; OR: odds ratio; CI: confidence interval.
aAll estimates adjusted for age and sex; p-trend for association = 0.001, OR (95% CI) = 0.91 (0.87–0.96). Adjusting in addition for 
smoking before disease onset, history of infectious mononucleosis, sun exposure, body shape at age 15, education, and consumption of 
fatty fish: p trend = 0.025, OR (95% CI) = 0.94 (0.89–0.99). The effect estimate did not materially change when adjusting in addition 
for supplementation during adolescence in the summer.
bReference group consists of those who reported neither an intake of cod liver oil liquid nor capsules.
cP value < 0.05.
dP value < 0.0001.
 at Universitetsbiblioteket i Bergen on September 7, 2015msj.sagepub.comDownloaded from 
M Cortese, T Riise et al.
http://msj.sagepub.com 7
There are alternative explanations to our findings. 
Adolescence might be the most sensitive period in 
which vitamin D unfolds its observed immunomodu-
latory effects30 or is of importance in the terminal 
phase of brain development. Another explanation 
could be that vitamin D supplementation during dif-
ferent periods in life might not lead to comparable 
serum levels. No age-dependent difference was, how-
ever, experimentally found in how dietary vitamin 
amounts translate into serum levels.25
Our results might also be due to chance, but this is 
unlikely considering the strong association and con-
formity with previous findings. We adjusted the esti-
mates for other known environmental risk factors, 
but we cannot exclude the possibility of residual 
confounding.
Alternatively, the inverse association between cod 
liver oil use during adolescence and MS risk might be 
due to a longer period of exposure rather than the 
right timing. Adolescent cod liver oil users may be 
more likely to have additionally consumed the sup-
plement during the other periods resulting in a longer 
exposure. However, when analyzing continuous 
supplementation from birth over increasingly longer 
periods, the strength of association did not steadily 
increase. The longest supplementation period was 
less strongly associated with a reduced MS risk than 
the shorter ones.
Lastly, our findings might be due to the protective 
effect of other cod liver oil ingredients. Vitamin A and 
E as well as omega-3 fatty acids have become of 
interest as possible disease-modifying candidates of 
MS.31–33 Fewer studies focused on a risk-modulating 
potential and results are not consistent. A U-shaped 
pattern of association between serum vitamin A levels 
and MS risk was reported in a registry-based smaller 
cohort study.34 However, intake of carotenoids, vita-
min E and omega-3 fatty acids assessed by food fre-
quency questionnaires was unrelated to disease risk in 
two large cohorts of women.35,36 We cannot exclude 
the possibility that vitamin A in cod liver oil contrib-
uted to our findings. The dose-response relationship 
observed for use during adolescence might be attrib-
uted to a protective effect of vitamin A, which 
increases along with vitamin D in higher doses of cod 
liver oil. It is unknown whether this nutrient acts age-
dependently and could thus explain the findings on 
the timing of exposure to cod liver oil. Salzer and col-
leagues reported similar associations for younger par-
ticipants (16–26 years) as in the entire cohort.34 Even 
if age at exposure was not addressed in detail, this 
observation contradicts somewhat the presence of a 
strong age-dependent effect for vitamin A. Moreover, 
evidence for an age-varying action of vitamin D exists 
beyond studies focusing on dietary sources, and thus 
independent of vitamin A.4
The MS prevalence is lower in populations with con-
sumption of fish,37 and earlier studies suggested an 
inverse association between fish consumption and 
MS.4,38 Focusing on vitamin D-rich fatty fish, we 
found that consuming it during adolescence might be 
protective against the disease. The association was 
similar but no longer significant after adjusting for 
cod liver oil use. Our study might be underpowered to 
show subtle associations.
Previous studies investigating and comparing associ-
ations in different age periods in humans were smaller 
and could not account for all of the known risk factors 
of MS in the analyses.4,5 In this present large case-
control study we analyzed cod liver oil supplementa-
tion, widely used in the Norwegian population, as a 
dietary proxy for vitamin D intake and serum levels. 
Investigating and comparing various age periods we 
found evidence of clear age differences in how vita-
min D might affect MS risk even after adjusting for 
possible confounding.
Case-control studies, although efficient to conduct 
and suited to study past exposures in detail, are sub-
ject to methodological limitations. Despite the popu-
lation-based sampling of both cases and controls, 
selection bias could, for instance, be an issue consid-
ering the different response rates between both 
groups. Compared to those included in the study, indi-
viduals not responding could have a different distri-
bution of some of their main characteristics affecting 
the correlation between exposure and disease. We do 
not have any information on such a possible relation, 
but we found a higher proportion of controls with the 
highest level of education compared to the cases, indi-
cating a higher socioeconomic status in controls. We 
accounted for this by adjusting for confounding by 
education.
Recall bias is another potential threat to the validity of 
findings in case-control studies. Nevertheless, the 
overall proportion of participants reporting cod liver 
oil use did not differ among cases and controls, and it 
is unlikely that participants were biased in recalling 
the timing of this supplementation. Knowledge about 
the period in life most susceptible to MS risk modifi-
cation is not yet established.
In order to reduce the risk for misclassified responses, 
non-differential due to memory issues in general and 
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differential due to deteriorating cognitive function in 
MS patients, only cases with a maximum disease 
duration of 10 years were eligible for the study. 
Furthermore, the age-period scale used to explore 
supplementation habits was adapted to the Norwegian 
school system to facilitate recall. In addition, partici-
pants were encouraged to ask their parents for help to 
correctly reconstruct past exposures if needed.
In conclusion, our findings suggest that adolescence 
might be an important postnatal age-period for an 
MS risk-reduction. Commonly used doses of vita-
min D contained in cod liver oil might contribute to 
modify MS risk when supplemented throughout 
adolescence. Further studies are needed to confirm 
our findings and to investigate whether higher doses 
might potentially be as protective during childhood 
or adulthood.
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Preclinical Disease Activity in Multiple
Sclerosis: A Prospective Study of
Cognitive Performance prior
to First Symptom
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Objective: To prospectively investigate potential signs of preclinical multiple sclerosis (MS) activity and when they
are present prior to first symptom using data from a historical cohort.
Methods: We linked the cognitive performance of all Norwegian men born 1950–1995 who underwent conscription
examination at age 18 to 19 years to the Norwegian MS registry to identify those later developing MS, and randomly
selected controls frequency-matched on year of birth from the Norwegian Conscript Service database. In this nested
case–control study, cognitive test scores were available for 924 male cases and 19,530 male controls. We estimated
mean score differences among cases and controls (Student t test) and the risk of developing MS comparing lower to
higher scores (Cox regression) in strata of years to clinical onset.
Results: Men developing first clinical MS symptoms up to 2 years after the examination scored significantly lower
than controls (D50.80, p50.0095), corresponding to a 6 intelligence quotient (IQ)-point difference. Those scoring
lowest, that is, >1 standard deviation below the controls’ mean, had an increased MS risk during the 2 following
years (relative risk5 2.81, 95% confidence interval5 1.52–5.20). Whereas results were similar for relapsing–remitting
MS cases (RRMS), those developing primary–progressive MS (PPMS) scored a significant 4.6 to 6.9 IQ points lower
than controls up to 20 years prior to first progressive symptoms.
Interpretation: RRMS may start years prior to clinical presentation, and disease processes in PPMS could start deca-
des prior to first apparent progressive symptoms. Cognitive problems could be present in both MS forms before
apparent symptoms. Apart from potential implications for clinical practice and research, these findings challenge our
thinking about the disease.
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Multiple sclerosis (MS) is a demyelinating disease ofthe central nervous system that is thought to be
caused by an interplay of genetic and environmental fac-
tors, but whose etiology is ultimately unknown.1 It is the
most common nontraumatic disabling neurologic disease
of young adults, constituting a considerable burden for
the individual and the health care system.2,3
In MS, substantial lesion load on brain magnetic
resonance imaging (MRI), cognitive dysfunction, and
disabling fatigue can be detected as early as at the first
clinical MS event, known as clinically isolated syndrome
(CIS).4–7 These early findings may indicate long-lasting
disease processes. Disease activity on MRI can occasional-
ly even be detected before the first neurological symp-
toms become apparent. In these individuals with
radiologically isolated syndrome (RIS), brain lesions sug-
gestive of the disease may be incidentally identified on
MRI performed for reasons other than suspicion of MS.8
Although 30 to 45% of these cases proceed to develop
CIS over several years,9,10 RIS is currently not recognized
as a separate MS phenotype due to the absence of clinical
symptoms and remains therefore usually untreated.10,11
RIS is, however, associated with cognitive impairment
detectable by thorough cognitive testing,12,13 suggesting
that maybe not all RIS cases are asymptomatic.
Although these early findings suggest that MS
begins prior to clinical onset, the nature and timing of a
possible preclinical disease activity beyond radiological
signs is largely unknown. Most studies on the natural
history of the disease have focused upon detecting predic-
tors of conversion to CIS or MS,6,9,14 and disability pro-
gression.15,16 Two studies investigating cognitive function
in the preclinical phase of MS reported inconsistent find-
ings.17,18 One of these studies described a positive corre-
lation between school performance in future patients and
time to MS onset.18
As little is known about the preclinical phase of
MS, we prospectively investigated potential early MS
signs and their temporal occurrence in individuals who
later developed MS. For this purpose, we used cognitive
test scores of almost the whole male Norwegian popula-




We conducted a registry-based nested case–control study within
the historical cohort of almost all Norwegian men born 1950
through 1995 who participated in the mandatory Norwegian
conscription examination at age 18 or 19 years (n5 1,308,872).
To identify those who subsequently developed MS, the Norwe-
gian Conscript Service database was linked to the Norwegian
MS registry.19 The linkage was done by a Norwegian govern-
mental agency, Statistics Norway, using the national identification
number unique to every Norwegian citizen and resident. Six
male controls were randomly selected from the Conscript Service
database frequency-matched on year of birth to the cases in the
MS registry born in the years 1950 to 1995 (n5 3,526). This
resulted in a control population of 21,156 individuals. In this
study, we only included male MS cases from the MS registry
born in that period (n5 1,109). Hence, this corresponded to a
ratio of about 1:20 and a similar distribution of year of birth
between male cases and controls.
The study was approved by the Regional Committee for
Medical and Health Research Ethics for Western Norway (refer-
ence number 2013/1307). MS patients’ consent for the MS reg-
istry includes use of data for research purposes. The data set
issued for analyses contained anonymized information.
The Norwegian MS Registry and Biobank
For the current study, we used information on year of onset
and initial MS course from patients registered in the Norwegian
MS Registry, which was established to facilitate patient care and
promote MS research.19 At the time of the linkage for this
study, approximately 50 to 60% of all MS patients in Norway
were registered. This is estimated based on the Norwegian
National Patient Registry (NPR) containing International Statis-
tical Classification of Diseases, 10th Edition (ICD-10) MS
codes given to every patient at hospital admission, treatment at
day units or outpatient clinics (100% coverage), and to some
extent to the small proportion of MS patients treated only by
neurologists at private practices. The NPR does not include
information on year of onset or diagnosis and disease course.
The responsible authorities aim at a complete coverage of the
MS registry with focused registration efforts in some regions.
However, there are still some regional differences. Whereas
some neurological departments actively register patients, some
others have not developed this routine yet.
The Norwegian Conscript Service Database
The Norwegian Conscript Service database includes informa-
tion on about 90% of all Norwegian men collected at the man-
datory conscription examination before military service.
Physically and mentally disabled individuals, prison inmates,
and Norwegians living abroad or working at sea are commonly
among those not attending.20 The conscription examination
has been compulsory for women only since 2010. There were,
consequently, too few women to be considered in this study.
Age at testing shifted from predominantly 19 years for those
born before 1976 to 18 years for the birth cohorts thereafter.21
Cognitive performance was assessed by a comprehensive
validated timed test (53 minutes, 120 questions) including a
mathematical part (25 minutes, testing logical reasoning, arith-
metic, algebraic ability), a word synonym test (8 minutes, test-
ing verbal ability, abstract reasoning, memory), and a figure test
(20 minutes, testing logical and abstract reasoning).20,22 The
math and word synonym subtests are not identical, but quite
similar to the arithmetic and vocabulary parts in the commonly
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used intelligence quotient (IQ) test, the Wechsler Adult Intelli-
gence Scale (WAIS), and the figure subtest resembles Raven’s
Progressive Matrices, a nonverbal intelligence test.20,22 The
overall cognitive performance was rated on a 9-point standard
scale, the Stanine (Standard Nine) scale, with normally distrib-
uted single-digit scores ranging from 1 to 9 for lowest to high-
est performance (mean5 5, standard deviation [SD]5 2). This
score combines the standardized scores of the equally weighted
subtests. In the present study only the overall scores, not the
subtest scores, were available to us. The test–retest reliability
has been estimated to be 0.84 for the mathematical, 0.90 for
the vocabulary, and 0.72 for the figure test.20,22 The overall
Stanine score correlates well with the IQ score as measured by
WAIS (r5 0.75). The format of the mathematical test was
changed in the 1990s from answers in prose to multiple choice,
whereas the test content remained the same.20,22
Statistical Analyses
Statistical analyses were performed using Stata 14 (StataCorp,
College Station, TX).
We determined the mean and corresponding SD of the
cognitive Stanine scores within birth cohorts of 5 years from
1950 to 1995, which we used to derive standardized cognitive
scores for each studied individual to adjust for variations in
score means over the decades. The standardized scores were
subsequently centered on a mean of 5 and SD of 2 and used
for all the analyses. Missing cognitive scores were not imputed.
The difference (D) in mean standardized cognitive scores
between cases and controls was assessed using unpaired 2-sided
Student t test at a significance level of 0.05. All comparisons
were drawn to the control group as a whole. Cases were
assessed overall and in subgroups according to initial disease
course: relapsing–remitting MS (RRMS) and primary–progres-
sive MS (PPMS). Additionally, MS patients were stratified into
years from examination to first clinical MS symptom (2-year
groups from 1–2 to 33–34 and 35 years, for cases overall and
the subgroup of RRMS and 10-year groups, 1–10, 11–20, 21–
30,> 30 years, for PPMS to account for lower prevalence and
later age at clinical onset than RRMS23). Misclassification of
time to clinical disease onset is possible in some patients born
in the mid-1970s who were affected by the shift in conscription
age from 19 to 18 years. In a sensitivity analysis, we excluded
cases born in the years 1972 to 1978 to estimate the effect of a
potential misclassification due to this change in testing age.
Furthermore, we calculated the proportion of men scoring low-
est during the examination to capture future patients, who may
have performed lower than expected. This was defined a priori
as a score >1 SD below the mean score among controls, which
corresponded to a score of <3 on the Stanine scale. The cutoffs
1 to 2 SD are often used to differentiate between cognitively
impaired and unimpaired individuals in MS research and served
as orientation for the cutoff selection in this study.4,5,12 We
used Cox proportional hazards models to estimate the risk of
developing MS in the years following the conscription examina-
tion, comparing those scoring lowest to the remaining individu-
als. Individuals contributed with time at risk from the year of
the cognitive test to the year of MS onset or end of follow-up
(2013), whichever occurred first. We performed separate analy-
ses within the strata of years to clinical MS onset without
assuming constant hazard ratios across strata. Men developing
MS after the period of interest were included in the analyses
and censored. We reported relative risk (RR) and 95% confi-
dence interval (CI). Additionally, we adjusted the probability
value conservatively for multiple comparisons by applying a
Bonferroni correction.
Results
Cognitive scores were available for 924 male cases and
19,530 male controls and were approximately normally
distributed in both groups. Median year of birth was
similar across quartiles of cognitive performance among
cases and controls (Table 1). Mean age at clinical onset
in RRMS cases was similar across quartiles of cognitive
performance. Cases with PPMS had first clinical symp-
toms on average later in life than cases with RRMS.
Those with lower scores experienced the first symptoms
of PPMS at a younger age compared to those with
higher scores.
Cognitive Performance prior to Clinical MS
Onset
Only men with clinical onset of MS up to 2 years after
the conscription examination scored significantly lower
in the stratified analyses compared to the control group
(n5 42, D5 0.80, 95% CI5 0.20–1.41, p5 0.0095).
This difference corresponds to 6 points on the IQ scale
(mean5 100, SD5 15). The results were similar when
we excluded cases born 1972–1978 from this group
(n5 34, D5 1.04, 95% CI5 0.36–1.71, p5 0.0025,
7.8 IQ points). There was no significant overall differ-
ence in cognitive scores between the controls and men
who later developed MS (Table 2). Furthermore, the risk
of developing MS after the examination was significantly
higher the following 2 years among those scoring lowest,
that is, >1 SD below the controls’ mean (40.5% of cases
vs 19.4% of controls, RR5 2.81, 95% CI5 1.52–5.20,
p5 0.001, Bonferroni correction for 18 tests: p5 0.018),
compared to the remaining individuals (Fig 1). However,
there was no association between scoring this low
(19.9% of cases vs 19.4% of controls) and the risk of
MS beyond 2 years after conscription (RR5 1.02, 95%
CI5 0.86–1.21).
Cognitive Performance according to Initial
Disease Course
When repeating the analyses in individuals later develop-
ing MS, stratified for initial disease course, findings in
those who developed RRMS were consistent with the
results in all cases. Whereas future patients showed
ANNALS of Neurology
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overall no cognitive difference compared to the controls
(see Table 2), we observed significantly lower scores only
in those developing first symptoms up to 2 years after
the examination (n5 38, D5 0.78, 95% CI5 0.14–
1.42, p5 0.016). In line with the findings in all cases,
the risk of MS was significantly higher only in the 2
years following the examination in those performing >1
SD below the controls’ mean (RR5 2.69, 95%
CI5 1.41–5.16, p5 0.003, Bonferroni correction for 18
tests: p5 0.054). There was no association beyond the 2
following years (RR5 0.98, 95% CI5 0.80–1.18).
However, among men later developing PPMS we
observed significantly lower mean scores compared to the
controls in those who experienced the first progressive
symptoms up to 20 years later (Fig 2). The differences
corresponded to 4.6 to 6.9 IQ points. There were only 6
cases developing PPMS> 30 years after the examination
(mean score5 5.46, p5 0.58). The risk of PPMS was
TABLE 2. Comparison of Cognitive Performance at Conscription of Male Individuals Who Later Developed MS
and Male Controlsa
Cognitive Test Scores, Stanineb
No. Mean6 SD D (95% CI)c pd
Controls 19,530 5.006 2.00 — —
Cases
All 860 4.916 1.99 0.10 (20.04 to 0.23) 0.17
RRMS 710 4.946 1.98 0.06 (20.09 to 0.21) 0.42
PPMS 110 4.596 2.03 0.41 (0.04 to 0.79) 0.03
aIncluding future cases with conscription examination prior to clinical MS onset and all controls.
bStandard scale from 1 to 9 indicating lowest to highest performance, with mean5 5 and SD5 2. Scores are standardized on 5-year birth cohorts.
One point on the scale corresponds to 7.5 intelligence quotient points.
cMean score difference D between controls (all) and cases (all and stratified according to initial MS course).
dProbability value of 2-sided unpaired Student t test.
MS5multiple sclerosis; Stanine5 Standard Nine scale; SD5 standard deviation; CI5 confidence interval; RRMS5 relapsing–remitting MS;
PPMS5primary–progressive MS.
TABLE 1. Characteristics of Males Who Developed MS in Their Life and Male Controls Born 1950–1995, by
Quartiles of Their Cognitive Test Scores at Conscription at Ages 18 to 19 Years in Norwaya
Quartiles of Cognitive Stanine Scores,b,c Mean
2.53, n5 5,410 4.39, n5 4,923 5.74, n5 5,732 7.75, n5 4,389
Year of birth, median (SD)
Controls 1961 (8.7) 1964 (8.9) 1960 (8.2) 1962 (8.8)
Cases 1961 (8.4) 1966 (8.8) 1960 (7.2) 1963 (8.5)
Age at clinical onset, mean yr (SD)
RRMS 30.2 (7.8) 31.1 (8.0) 31.9 (8.0) 30.4 (8.6)
PPMS 35.3 (8.4) 33.3 (9.6) 38.3 (7.9) 38.3 (8.1)
aIncluding all cases and controls with cognitive score assessed at conscription.
bStandard scale scores: 1–9 (lowest to highest performance), mean5 5, SD5 2, standardized on 5-year birth cohorts.
cMissing data: 7.7% for cognitive score among controls and 16.7% among male cases in the Norwegian MS registry born 1950–1995; 0% for year
of birth; 1.2% for age at clinical onset among cases with cognitive score. 4.4% have unknown status or missing data on the MS form among cases
with cognitive score.
MS5multiple sclerosis; Stanine5 Standard Nine scale; SD5 standard deviation; RRMS5 relapsing–remitting MS; PPMS5primary–progressive
MS.
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significantly elevated during 20 years following the cogni-
tive test in men scoring >1 SD below the mean perfor-
mance among controls compared to men with relatively
higher scores (Fig 3). The estimates were no longer sig-
nificant after applying a conservative Bonferroni correc-
tion for 4 tests (1–10 years: p5 0.15; 11–20 years:
p5 0.14).
Discussion
In this prospective study, we found that men who experi-
enced their first clinical MS symptom up to 2 years after
their conscription examination at age 18 to 19 years
scored significantly lower on the cognitive test than the
controls by an equivalent of 6 IQ points. This finding
was consistent for cases with RRMS. However, in future
cases of PPMS we observed significantly lower scores in
those with clinical onset up to 20 years later. Our find-
ings imply that MS may start with not easily detectable
symptoms prior to the apparent clinical MS onset. Cog-
nitive dysfunction may, thus, be an early sign of disease.
Only a few studies have examined possible signs of
disease activity prior to clinical MS onset. Consistent
with our observations, a prospective study using the
Swedish Military Conscription Registry found overall no
difference in cognitive function score.17 Case identifica-
tion was, however, based on nonvalidated ICD MS diag-
nosis codes from the Swedish National Patient Registry,
FIGURE 2: Relative mean cognitive Stanine (Standard Nine
scale) scores at conscription in men aged 18 or 19 years
who later developed primary–progressive multiple sclerosis
(PPMS), stratified in 10-year groups to clinical onset, com-
pared to controls, indicating the difference between the
overall mean score among the 19,530 controls (mean-
55.00, 95% confidence interval [CI]54.98–5.03) and mean
scores in strata of future PPMS cases according to time to
clinical onset, determined using unpaired Student t test.
Stanine scores are on a standard scale from 1 for 9, indicat-
ing lowest to highest performance (mean55, standard
deviation52) and are standardized on 5-year birth cohorts.
One point on the scale corresponds to 7.5 intelligence quo-
tient points.
FIGURE 3: Association between low cognitive scores at con-
scription in men aged 18 or 19 years and the risk of devel-
oping primary progressive multiple sclerosis (MS) in the
following years, reflecting the risk of developing primary
progressive MS in the years following the conscription
examination with cognitive testing comparing those scoring
>1 standard deviation below the controls’ mean to the
remaining individuals. CI5 confidence interval; RR5 relative
risk.
FIGURE 1: Association between low cognitive scores at con-
scription in men aged 18 or 19 years and the risk of devel-
oping multiple sclerosis (MS) in the following years,
reflecting the risk of developing MS in the years following
the conscription examination with cognitive testing compar-
ing those scoring >1 standard deviation below the controls’
mean to the remaining individuals. CI5 confidence interval;
RR5 relative risk.
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and the authors could not estimate differences according
to time to clinical MS onset, as we present in our analy-
ses. The authors concluded therefore that cognitive func-
tion was not indicative of early disease processes.
Another study found a significantly worse high school
performance during final years at school in students who
later developed MS compared to those who did not.18
Interestingly, performance during the last year was corre-
lated with the time interval to clinical onset of MS, sug-
gesting prodromal disease activity in those closest to
onset.18 However, because this was a small case–control
study, the power was probably insufficient to examine
this aspect in detail. Furthermore, 2 smaller studies sug-
gested that individuals with RIS have a similar cognitive
impairment profile to that of patients with RRMS, but
the temporal relationship was not assessed.12,13 As we
investigated the presence of subtle MS symptoms prior
to the apparent disease onset, our findings do not
exclude the possibility that disease activity detected on
MRI and laboratory abnormalities might precede clinical
onset of MS by an even longer period.8,9
Our finding in the total MS population of worse
cognitive performance in those developing MS up to 2
years after the conscription examination was driven by
RRMS. Intriguingly, those later developing PPMS per-
formed worse than the controls during cognitive tests at
age 18 to 19 years, although they did not experience pro-
gressive symptoms until up to 2 decades after the con-
scription examination. RRMS and PPMS are thought to
be different phenotypes of the same disease rather than
different disease entities23 and might start at a similar
but present clinically at different periods in life. Hence,
disease processes in patients with PPMS might start
many years prior to onset of progressive symptoms
around the age of 40 years. Characteristics of PPMS like
the clinical onset later in life, its progressive nature, and
the speed at which disability accumulates, seem to paral-
lel properties of secondary progressive MS (SPMS),23
which evolves eventually in many patients with initially
relapsing disease. Accordingly, a long subclinical phase
with not easily noticeable signs might precede the clinical
onset of PPMS and parallel the first stage of RRMS.
Men developing PPMS showed an impact on cog-
nitive function farther from clinical onset than those
developing RRMS. Although cognitive impairment is a
common MS symptom, independent of the disease
course,24 many studies have tried to identify in which
form it is most prevalent, yielding inconsistent find-
ings.25 Although it appears that patients in their second-
ary progressive disease phase tend to be most affected,
patients with PPMS seem to be more frequently and
severely affected than those with relapsing MS,
independent of disability status.26,27 Although motor
symptoms are predominantly present in PPMS often due
to pronounced diffuse spinal cord pathology, including
atrophy, patients also appear to suffer widely from
marked cortical brain atrophy, which is a correlate of
cognitive dysfunction.25 Moreover, cortical demyelin-
ation, which is also associated with cognitive impair-
ment,28 seems to be more pronounced in PPMS and
SPMS compared to RRMS patients.29
There are different possible explanations for our
findings on cognitive impairment. Cognitive dysfunction
might precede first obvious MS symptoms. Diffuse path-
ological processes in the brain13,28 might increasingly dis-
rupt neuronal connectivity and lead to subtle cognitive
disturbances that are compensated for in daily life but
unveiled by thorough testing. Considering research on
the role of cognitive reserve, our study might even have
underestimated the rate of those revealing preclinical dis-
ease processes.30 Men with higher efficiency in meeting
cognitive demands, thanks to higher education and cog-
nitively stimulating occupational or leisure activities,
might compensate for potential ongoing brain pathology
and still score higher in the test. Lower cognitive scores
before clinical onset may also result from symptoms asso-
ciated with cognitive disturbances, such as depression or
fatigue, and preceding the first focal neurologic
attack.24,31 We cannot exclude the possibility that some
future cases were affected by such symptoms during the
examination, which might have negatively influenced
their test performance by lack of drive and concentration.
In that case, cognitive impairment may be considered an
indirect early disease sign, especially because we did not
find any overall performance difference. There is current-
ly no evidence that depression or fatigue may be risk fac-
tors of MS and require adjustment as possible
confounders. Furthermore, we need to consider the possi-
bility that our findings might be due to confounding by
established or potential MS risk factors. Higher educa-
tion can influence cognitive performance and has been
associated with lower MS risk in previous studies. It
could therefore confound the observed associations.32,33
However, it is again unlikely that differences in schooling
or other factors can explain that we only found evidence
of lower performance when considering the temporal
relationship, but no difference overall. If preclinical dis-
ease processes influenced schooling and school perfor-
mance in a negative way,18 adjusting for differences
could lead to a false-negative result. Alternatively, the
observations might be biased due to competing risks, like
emigration or premature death, occurring with higher
probability in controls with lower or in cases with higher
cognitive performance before they can develop MS. This
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risk constellation and systematic difference is, however,
unlikely. Lastly, it cannot be excluded that our findings
might be due to chance, but statistical significance and
evidence from previous studies on early cognitive prob-
lems in MS argue against this.4,14
Our study has several strengths. It is a large pro-
spective study based on objective test measures of almost
the whole male Norwegian population over several deca-
des. As the controls were randomly selected from this
cohort, selection bias is unlikely. The MS registry, used
to identify future cases, contains diagnoses of MS
patients from all over the country verified by neurologists
according to the McDonald criteria.34 Hence, misclassifi-
cation was probably rare in this study. We could prospec-
tively investigate a potential impact on cognitive function
and, for the first time, when it was detectable prior to
disease manifestation. Our results unveiled a possible
latent MS phase with subtle symptoms and relativize the
idea of a clinical threshold in MS.
Our findings confirm the importance of early diag-
nosis34 and initiation of disease-modifying treatment.35
They may also justify screening for cognitive dysfunction
in early disease phases, allowing prognostic considerations
and prompt interventions to maximize cognitive reserve
if cognitive rehabilitation proves effective.30,36,37 Screen-
ing for cognitive impairment could also be important for
the evaluation of RIS cases regarding their risk of conver-
sion to MS and approaches to their follow-up including
potential disease-modifying treatment.12,13 In addition,
our observations could bring us further in understanding
differences between RRMS and the less-well understood
PPMS, which is today resistant to standard treatment.25
Our findings should, furthermore, be considered for the
design of future MS risk factor studies to minimize
reverse causation issues. Taken as a whole, these findings
might challenge our thinking about MS and reignite the
discussion about classification of different disease stages,
possible onset symptoms, and diagnostic criteria.11
Potential limitations need to be considered when
interpreting these results, because the disease is more
prevalent in women,24 one weakness is that the study
was restricted to men. However, external validity for
white men is high, as this study is based on the whole
male population of a Western country over several deca-
des. Apart from a potentially higher prevalence in men,
there is currently no evidence that cognitive impairment
in male and female MS patients displays different charac-
teristics.38 Nevertheless, further studies are needed to
exclude major differences. Furthermore, it is possible that
there is misclassification of 1 year regarding time to clini-
cal MS onset in some future patients born around 1975,
for whom testing age was shifted from 19 to 18 years.
However, the results in cases closest to clinical MS onset
remained unchanged, when excluding those born 1972
through 1978 from the analysis. Another limitation may
be that our findings were based on one performance
measurement per person. We could, therefore, not exam-
ine the individual development of cognitive function
over time. Furthermore, additional information on level
of education and prevalence of depression in the partici-
pants would have been ideal, but it was not available to
us. Moreover, the unavailable subtest scores could have
provided further information on the potentially affected
cognitive area. However, all subtests are specifically timed
and probably we would therefore primarily obtain, with
all of them, a measure of processing speed efficiency, as
we do with the composite score, although a specific neu-
ropsychological test of information processing speed was
not performed. As processing speed is the cognitive abili-
ty most commonly affected in MS,24 tests specifically
assessing this skill predict best cognitive impairment in
different neuropsychological test batteries and are thus
recommended as a screener tool in clinical time-limited
settings.39,40 Furthermore, the incomplete MS registry
coverage might also have led to bias. Differences in regis-
tration are, however, due to regional hospital compliance,
and a systematically differential registration according to
specific disease characteristics is unlikely. It is furthermore
unlikely that there are regional differences in characteris-
tics of the MS patient population and cognitive scores
that could create a major bias in the estimation of the
true impact on cognition. Moreover, we chose, a priori,
1 SD as cutoff to investigate the MS risk in those with
low performance; lower cutoffs, used in some previous
studies on cognitive impairment in MS patients, might
have yielded different results. However, we intended to
capture future cases performing lower than expected, in
other words, men who began to be affected cognitively,
but were not necessarily or not yet cognitively impaired.
Lastly, the cognitive test was not validated specifically for
individuals developing MS and is supposed to screen and
rank cognitive function compared to the norm. Conse-
quently, it is possible that cognitive tests tailored for MS,
and thus more sensitive for MS-specific areas of cognitive
impairment, might detect even more subtle differences
between future cases and controls.
In conclusion, our study provides evidence that MS
might be preclinically active with not readily detectable
symptoms several years prior to the first classic MS attack
or decades prior to the first progressive MS symptoms.
Cognitive function may be affected even before the first
focal symptoms occur. Monitoring changes in cognitive
function in individuals with CIS and especially RIS may
contribute to identifying those at risk of MS.
ANNALS of Neurology
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Appendix A: EnvIMS-Q in Norwegian  
A
1
Skjemaet skal leses av en maskin. Det er derfor viktig at du legger vekt på følgende ved utfyllingen:
• Bruk blå eller sort kulepenn.
• I de små avkrysningsboksene setter du et kryss for det svaret som du mener passer best, slik: 
• Hvis du mener at du har satt kryss i feil boks, kan du rette det ved å fylle boksen helt, slik: 
• Der du ikke kan svare på et spørsmål vennligst bruk “Vet ikke” eller “Husker ikke” avkrysningsboksene.
X
1. Hvilket år er du født?
19
SEKSJON 1: BAKGRUNNSDATA
4. Fyll ut kjønn og fødselsår for hvert søsken (inkludert halvsøsken og adoptivsøsken):                         Jeg er enebarn 
 1 2 3 4 5 6
Fødselsår:
Kjønn (M/K) M   K  M   K  M   K  M   K  M   K  M   K 
SEKSJON 2: SOLVANER
5. Om sommeren: Hvor mye utendørsaktiviteter (lek, idrett, tur, hagearbeid, jobb) hadde du? 
            Lite Middels Ganske mye Ute stort sett hele tiden
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     
I de siste tre årene ................     
1. Sett ett kryss på det tallet under fargen som best passer din naturlige hudfarge ved å sammenligne med huden på innersiden av overarmen. 
1 2 3 4 5 6 7 8 9 10
2. Hvordan reagerer huden din første gang du soler deg 
om sommeren hvis du ikke bruker krem med solfaktor? 
1. Jeg blir alltid solbrent og jeg blir aldri brun ...........  
2. Jeg blir vanligvis solbrent og blir mindre
 brun enn andre  .....................................................  
3. Jeg blir av og til solbrent og blir brun
 omtrent som de fl este andre .................................  
4. Jeg blir sjeldent solbrent og blir lett brun  .............  
3. Hva er din opprinnelige hårfarge?
(sett ett kryss) 
1. Svart ...............  
2. Mørkbrun ........  
3. Brun ................  
4. Blond, gul .......  
5. Rød .................  
4. Hvilken øyefarge har du? 
(sett ett kryss) 
1. Svart ...............  
2. Brun ................  
3. Grå, grønn ......  
4. Blå ..................  
2. Hvilken utdanning er den høyeste du, faren din og moren din har fullført?
(sett ett kryss for hver av dere tre)
 Du selv Far Mor
7-årig folkeskole eller mindre .............................    
Grunnskole 9-10 år ..........................................    
Gymnas/ Videregående skole (11-13 år) ................    
Høgskole/Universitet (mer enn 14 år) ....................    
Vet ikke.........................................................    
3. Hvilken etnisk gruppe tilhører dine foreldre       
 Far Mor  Far Mor
1. Norsk/europeisk/annen vestlig ................    4. Afrikansk ............................  
2. Samisk .......................................................    5. Midtøsten  ..........................  










8. Hvor ofte var du på badeferie i ”syden”? 
Alder                      Aldri/sjelden 1 uke i året eller mindre 2-3 uker i året    4 uker eller mer i året
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     
I de siste tre årene ................     
9. Hvor ofte brukte du krem med solfaktor (forsøk å tenke deg et gjennomsnitt)? 
Alder                      Aldri/sjelden  Av og til Ganske ofte Nesten alltid
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     
I de siste tre årene ................     
10. Hvor ofte har du solt deg i solarium? 
Alder Aldri/sjelden Mindre enn 1 gang pr. år Mindre enn 1 gang pr. måned En gang pr. måned eller oftere
16-20 år ......................     
21-25 år ......................     
26-30 år ......................     
SEKSJON 3: KOSTHOLD
Vi er interessert i å få kjennskap til hvordan kostholdet ditt vanligvis var i tenårene (fra 13 til 19 års alder) før du eventuelt fl yttet hjemmefra.
Først vil vi vite hvor ofte du spiste fi sk og ber deg fylle ut spørsmålene så godt du kan.
1. Tilgangen på fi sk kan variere gjennom året. Vær vennlig å markere i hvilke årstider du vanligvis spiste de ulike fi skeslagene
    (sett gjerne fl ere kryss). 
 Vinter Vår Sommer Høst Aldri/sjelden
Torsk, sei, hyse, lyr .....      
Kveite, fl yndre  ............      
Laks, ørret ..................      
Makrell ........................      
Sild .............................      
2. Med tanke på de periodene av året der du spiste fi sk, hvor ofte pleide du å spise følgende til middag? (sett ett kryss pr. linje) 
  Aldri/sjelden 1 pr.mnd. 2-3 pr.mnd. 1 pr.uke 2 pr.uke 3+ pr.uke
Torsk, sei, hyse, lyr .....       
Kveite, fl yndre  ............       
Laks, ørret ..................       
Makrell ........................       
Sild .............................       
7. Hvor mye tid har du tilbrakt utendørs i forbindelse med arbeidet ditt eller studiene dine? 
Alder  Inne stort sett hele tiden Ute stort sett hele tiden Samme tid inne og ute
16-20 år .............................................................................     
21-25 år .............................................................................     
26-30 år .............................................................................     
6. Om vinteren: Hvor mye utendørsaktiviteter (lek, idrett, tur, hagearbeid, jobb) hadde du? 
            Lite Middels Ganske mye Ute stort sett hele tiden
0-6 år ....................................     
7-12 år (barneskolen) ...........     
13-15 år (ungdomsskolen) ....     
16-18 år (videregående) .......     
19-24 år ................................     
25-30 år ................................     







3. Hvor ofte spiste du fi skelever fra du var 13 til 19 år gammel? 
 Aldri   1-3 pr.år       4-6 pr.år   7-9 pr.år 10+ pr.år Vet ikke
             
7. Hva slags fett brukte du vanligvis på brødet?
    (sett gjerne fl ere kryss)
 Brukte ikke fett på   
 brødet  Plantemargarin Smør Vet ikke
    
8. Dersom du brukte fett på brødet, hvor tykt lag pleide du å smøre 
på? (En kuvertpakke med margarin veier 12 gram) (sett ett kryss)
 Skrapet Tynt lag Godt dekket Tykt lag
 (3 g) (5 g) (8 g) (12 g)  
    
5. Da du var 13 til 19 år gammel, hvor mange brødskiver med følgende pålegg spiste du i gjennomsnitt: (sett ett kryss for hver linje) 
 0 pr.mnd. 1-3 pr.mnd. 1 pr.uke 2-3 pr.uke 4-6 pr.uke 7-9 pr.uke 10+ pr.uke
Makrell i tomat, røkt makrell ....         
Kaviar/”Svolvær postei” ..........         
Sardiner, sild, ansjos ...............         
Laks (gravet/røkt) .....................         
Annet fi skepålegg ....................         
4. Da du var 13 til 19 år gammel, hvor ofte spiste du følgende matvarer: (sett ett kryss for hver linje) 
  Aldri Mindre enn 1 pr.mnd. 1-3 pr.mnd. 1 pr. uke 2-3 pr.uke 4+ pr.uke
Kjøtt, (biff, stek, koteletter) og kjøttprodukter
(kjøttkaker, kjøttpudding, pølser) ................         
Røkt kjøtt ....................................................         
Røkte pølser (wienerpølser)  .......................         
Røkt fi sk .....................................................         
Røkt ost ......................................................         
9. Hvor ofte brukte du kosttilskudd da du var 13 til 19 år gammel? For fl ytende tran og tranpiller, vær vennlig å markere i hvilke 
årstider du brukte dem. Dersom du brukte dem hele året, sett ett kryss for vinter, og ett kryss for resten av året. 
 Aldri/sjelden 1-3 pr. mnd. 1 pr. uke 2-3 pr. uke 4-6 pr. uke 7+ pr. uke  
Tran
   Om vinteren .......................        
   Resten av året  ..................        
Tranpiller
   Om vinteren .......................        
   Resten av året  ..................        
Fiskeoljekapsler ....................        
Multivitaminer eller annet
kosttilskudd slik som
Sanasol, Vitaplex, Biovit, 
Kostpluss og Vitamineral ......       
6. Hvor mange brødskiver spiste du hver dag i gjennomsnitt?
11. Hva slags multivitamin/kosttilskudd brukte du i følgende aldere? (sett gjerne fl ere kryss) 
    7-12 år 13-15 år 16-18 år
 Aldri                   0-6 år          (barneskolen)     (ungdomsskolen)    (videregående)          19-24 år           25-30 år
Multivitaminer ...........................          
Kalsium .....................................          
Vitamin D ..................................          
Vitamin B12 ..............................          
Tran/Tranpiller ...........................          
Fiskeoljekapsler ........................          
10. Hvor mye tran pleide du å ta hver gang?
 Brukte ikke tran  ts. 1 ts.  ss. 1+ ss.
       
12. Ble du ammet?                                                                  Hvor mange måneder?
 Nei Vet ikke Ja 1-3 mnd. 4-6 mnd. 7-9 mnd. 10+ mnd.







                       Ja      Nei      Husker ikke                         Hvis, ja ble det tatt blodprøve for å stille diagnosen?
2. Har du hatt kyssesyken (mononukleose)?                                                                      Ja                        Nei            Husker ikke
                                                                   
       7-12 år 13-15 år 16-18 år  
Hvilken skoleklasse gikk du i da du hadde sykdommen?  0-6 år (barneskolen) (ungdomsskolen) (videregående) 19-24 år 25-30 år
           
                                                              Hvis ikke, husker du ihverfall hvilken årstid det var?
                          Vår         Sommer        Høst            Vinter     Husker ikke
             3. Husker du hvilken måned du hadde kyssesyken (01-12)?                                                               
4. Har du hatt urinveisinfeksjon (blærekatarr)? I så fall, prøv å huske når. 
                                    Alder (sett gjerne fl ere kryss)
 Nei Vet ikke Ja 0-6 år 7-12 år 13-15 år 16-18 år 19-24 år 25-30 år
                 
5. Har du noen gang hatt infeksjon med innvollsormer eller andre parasitter (amøber, bendelorm, mark i magen)
                                    Alder ved start
 Nei Vet ikke Ja 0-6 år 7-12 år 13-15 år 16-18 år 19-24 år 25-30 år
                 
1. Har du hatt noen av følgende sykdommer eller kirurgisk behandling? Prøv å huske hvilken skoleklasse du gikk i da du hadde sykdommen.
    (sett gjerne fl ere kryss)                                   Alder ved diagnose/sykdom
       7-12 år 13-15 år 16-18 år  
   Nei Vet ikke Ja 0-6 år (barneskolen) (ungdomsskolen) (videregående) 19-24 år 25-30 år
Fjernet mandlene .......................                   
Meslinger ...................................                   
Kusma .......................................                   
Røde hunder ..............................                   
Vannkopper ...............................                   
Lungebetennelse .......................                   
6. Har du hatt allergiske reaksjoner (øyekatarr, eksem, høysnue, astma) mot noen av det som er nevnt under? I så fall, angi omtrent 
hvilken alder du først merket disse symptomene
   Nei Vet ikke Ja 0-6 år 7-12 år 13-15 år 16-18 år 19-24 år 25-30 år
Pollen .........................................                   
Husstøv .....................................                   
Allergi mot kjæledyr og husdyr ..                   
Mat ............................................                   
Annen allergi ..............................                   
7. Har du eller har du hatt noen av følgende sykdommer? 
      Alder ved
   Nei Ja Vet ikke første diagnose
Systemisk lupus erythematosus (Lupus)                         år
Reumatoid artritt (leddgikt)                          år
Hypotyreose (lavt stoffskifte)                          år
Hypertyreose (høyt stoffskifte)                          år
Multippel sklerose                          år
Synsnervebetennelse                          år
Crohns sykdom                          år
Ulcerøs colitt                          år
Annet,                         år
presiser: ––––––––––––––––––––––––––––––––––––––––––––
      Alder ved 
   Nei Ja Vet ikke første diagnose
Diabetes mellitus type 1                          år
Cøliaki                          år
Psoriasis                          år
Leukemi (blodkreft)                          år
Hodgkins lymfom                          år
Annen type lymfom                          år
Føfl ekkkreft                         år
Annen type hudkreft                          år







SEKSJON 5: RØYKEVANER OG LIVSSTIL
1. Har du noen gang røykt daglig?  
Ja      Nei, aldri
     Hvis nei, gå til spørsmål 5
11. Har du jobbet med noen som pleide å røyke på din arbeidsplass?  
 Nei Ja
                
5. Da din mor var gravid med deg, pleide hun å røyke?
 Nei Vet ikke Ja           Hvor mange sigaretter
         røykte hun pr. dag?
                < 10       10 +  
8. Har noen i familien din hatt noen av følgende sykdommer? 
  Nei Far Mor Søsken Barn                              Vet ikke
Systemisk lupus erythematosus (Lupus) .......................       
Reumatoid artritt (leddgikt) ............................................       
Hypotyreose ..................................................................       
Hypertyreose .................................................................       
Multippel sklerose .........................................................       
Synsnervebetennelse ....................................................       
Crohns sykdom .............................................................       
Ulcerøs colitt .................................................................       
Psoriasis  .......................................................................       
Diabetes mellitus type 1 (insulinkrevende sukkersyke) .       
Cøliaki ............................................................................       
Leukemi .........................................................................       
Hodgkins lymfom ..........................................................       
Annen type lymfom .......................................................       
2. Hvis ja, hvor mange sigaretter røykte du igjennomsnitt pr. dag?
    Antall sigaretter hver dag
  Røykte ikke 1-4 sig. 5-10 sig. 11-20 sig. 21+ sig.
11-15 år  .........      
16-20 år  .........      
21-25 år  .........      
26-30 år  .........      
3. Hvor gammel var du da du
begynte å røyke daglig?
Alder:                      år
4. Hvor mange år har du
røykt tilsammen?
                              år
8. Har du bodd sammen med noen andre som pleide å røyke
inne i huset før du var 21 år?  
 Nei Ja                                               
     Hvem?         Hvor mange sigaretter røykte
             de inne huset pr. dag?
   Bror    < 10   10 +  
   Søster    < 10   10 +  
   Annen    < 10   10 +  
9. Har du bodd sammen med en partner eller noen andre
som pleide å røyke inne i huset fra du var 21 til 25 år?  
 Nei Ja        Hvor mange sigaretter røykte han/hun
              inne i huset pr. dag?                
                              
        < 10        10 +  
10. Har du bodd sammen med en partner eller noen andre
som pleide å røyke inne i huset fra du var 26 til 30 år?  
 Nei Ja        Hvor mange sigaretter røykte han/hun
              inne i huset pr. dag?               
        < 10        10 +  
6. Da du var barn, pleide faren din å røyke inne i huset?  
 Han var en   Nei, han røykte                           Hvor mange sigaretter røykte
 ikke-røyker       ikke inne     Vet ikke    Ja        han inne huset pr. dag?        
                                    < 10            10 +  
7. Da du var barn, pleide moren din å røyke inne i huset?  
 Hun var en   Nei, hun røykte                           Hvor mange sigaretter røykte
 ikke-røyker       ikke inne     Vet ikke    Ja        hun inne huset pr. dag?        
                                    < 10            10 +  
12. Hvilket diagram illustrerer best din fi gur på de forskjellige alderstrinn?
  
                        
  
5- år          
10-år ..........          
15-år ..........          
20-år ..........          
25-år ..........          
30-år ..........          
I dag ..........          
14. Hva er høyden din?                                             cm








SEKSJON 7: HORMONELLE FAKTORER
15. Hvordan var din fysiske aktivitet i fritiden da du var 13 til 19 år gammel? Tenk deg et ukentlig gjennom-
snitt for året. Skolevei regnes som fritid. besvar begge spørsmålene.
                                                                         timer per uke
    Ingen Under 1 1-2 3 eller fl ere 
Lett aktivietet (ikke svett eller andpusten)    
Hard fysisk aktivitet (svett og andpusten)    
1. Har du på din arbeidsplass vært betydelig eksponert for: 
      Hvor gammel var du da  Hvor mange år har Hva slags arbeid hadde du da
   Nei Vet ikke Ja eksponeringen startet? du vært eksponert? du ble eksponert?
Motorolje                          år                    år –––––––––––––––––––––––––––
Skjæreolje                          år                    år –––––––––––––––––––––––––––
Formolje                          år                    år –––––––––––––––––––––––––––
Hydraulikkolje                          år                    år –––––––––––––––––––––––––––
Turbinolje                          år                    år –––––––––––––––––––––––––––
Asfalt                          år                    år –––––––––––––––––––––––––––
Boreslam                          år                    år –––––––––––––––––––––––––––
Råolje                          år                    år –––––––––––––––––––––––––––
Narkosegasser                           år                    år –––––––––––––––––––––––––––
Organiske løsemidler*                          år                    år –––––––––––––––––––––––––––
*F.eks. avfettingsmidler, trikloroetylen, tetrakloroetylen, white spirit, tynnere, toluen, styren, xylen el. liknende
1. Hvor gammel var du da du fi kk din første menstruasjon?                     år                                                 2. Er du gravid nå?    Nei      Ja  
3. Har du vært gravid?    Nei      Ja     Om svaret er ja, vennligst oppgi utfallet og årstallet for graviditetene.
 Graviditet 1 Graviditet 2 Graviditet 3 Graviditet 4 Graviditet 5 Graviditet 6
Levende født ..................................      
          Ammet du barnet minst
         i en måned? ............................      
Abort (spontan abort eller
provosert abort ...........................      
Dødfødsel ...................................      
                                  
                                     År
5. Har du brukt P-piller (ikke mini-piller) av typen som kan tas i 3 uker
og deretter tas sukkerpiller i 1 uke, P-plaster eller vaginal P-ring?                                     
Nei      Ja   
Hvor gammel var du første gang du brukte slike prevensjonsmidler?                    år                 
                                                                                                                                                     
                                                                                                                        
 Hvor lenge brukte du slike prevensjonsmidler?
< 1 år       1-3 år        4-5 år        6-9 år         10+ år
                                                      
1. Helt til slutt vil vi gjerne vite om du har fått informasjon  fra andre ved utfylling av dette skjemaet, f.eks. din mor?
 Hvis ja, hvem? Mor 
 Far 
 Andre   
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